| Year |
Citation |
Score |
| 2020 |
Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: State of the art and future directions. Ca: a Cancer Journal For Clinicians. PMID 32478924 DOI: 10.3322/Caac.21613 |
0.419 |
|
| 2020 |
Patel MP, Kirkpatrick JP, Johnson MO, Healy P, Herndon JE, Lipp ES, Miller ES, Desjardins A, Randazzo D, Friedman HS, Ashley DM, Peters KB. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series. Journal of Neuro-Oncology. PMID 32140975 DOI: 10.1007/S11060-020-03446-3 |
0.362 |
|
| 2020 |
Desjardins A, Randazzo D, Chandramohan V, Peters KB, Johnson MO, Threatt S, Bullock CA, Herndon JE, Healy P, Lipp ES, Sampson JH, Friedman AH, Friedman HS, Ashley DM, Bigner DD. Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG). Journal of Clinical Oncology. 38: 2566-2566. DOI: 10.1200/Jco.2020.38.15_Suppl.2566 |
0.374 |
|
| 2019 |
Johnson MO, Kirkpatrick JP, Patel MP, Desjardins A, Randazzo DM, Friedman HS, Ashley DM, Peters KB. The role of chemotherapy in the treatment of central neurocytoma. Cns Oncology. CNS41. PMID 31686534 DOI: 10.2217/Cns-2019-0012 |
0.396 |
|
| 2019 |
Kim JY, Jackman JG, Woodring S, McSherry F, Herndon JE, Desjardins A, Friedman HS, Peters KB. Second primary cancers in long-term survivors of glioblastoma. Neuro-Oncology Practice. 6: 386-391. PMID 31555453 DOI: 10.1093/Nop/Npz001 |
0.327 |
|
| 2019 |
Patel MP, Woodring S, Randazzo DM, Friedman HS, Desjardins A, Healy P, Herndon JE, McSherry F, Lipp ES, Miller E, Peters KB, Affronti ML. Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 31440823 DOI: 10.1007/S00520-019-05039-X |
0.395 |
|
| 2019 |
Lipp ES, Healy P, Austin A, Clark A, Dalton T, Perkinson K, Herndon JE, Friedman HS, Friedman AH, Bigner DD, McLendon RE. MGMT: Immunohistochemical Detection in High-Grade Astrocytomas. Journal of Neuropathology and Experimental Neurology. 78: 57-64. PMID 30500933 DOI: 10.1093/Jnen/Nly110 |
0.325 |
|
| 2019 |
Desjardins A, Gromeier M, Herndon JE, Randazzo D, Threatt S, Lipp ES, Miller ES, Jackman J, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Peters KB, Johnson MO, Sampson JH, et al. Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial. Journal of Clinical Oncology. 37: 2060-2060. DOI: 10.1200/Jco.2019.37.15_Suppl.2060 |
0.459 |
|
| 2019 |
Randazzo D, Jackman J, Herndon J, Affronti M, Lipp E, Cort N, Desjardins A, Johnson M, Landi D, Ashley D, Friedman H, Glass O, Porter L, Peters K. Qolp-29. Mindfulness Meditation Practice In Malignant Glioma Patients Throughout Concomitant Radiation And Temozolomide: A Feasibility Study Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.849 |
0.324 |
|
| 2019 |
Barbour A, Healy P, Lipp E, Herndon J, Thomas L, Johnson M, Ashley D, Desjardins A, Randazzo D, Friedman H, Kirkpatrick J, Peters K. Hout-21. Characteristics Of Short-Term Survival In Patients With Glioblastoma: A Retrospective Analysis Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.486 |
0.317 |
|
| 2019 |
Peters K, Congdon K, Archer G, Woodring S, Jaggers D, Lipp E, Healy P, Herndon J, Soher B, Vlahovic G, Johnson M, Randazzo D, Desjardins A, Friedman H, Friedman A, et al. ATIM-31. SAFETY OF TUMOR-SPECIFIC PEPTIDE VACCINE TARGETING ISOCITRATE DEHYDROGENASE 1 MUTATION IN RECURRENT RESECTABLE LOW GRADE GLIOMA PATIENTS Neuro-Oncology. 21: vi8-vi8. DOI: 10.1093/Neuonc/Noz175.030 |
0.354 |
|
| 2019 |
Gromeier M, Brown M, Beuabier N, Yan H, He Y, Zhang G, Desjardins A, Herndon J, Bolognesi D, Friedman A, Friedman H, McSherry F, Lin X, Wei Z, Nair S, et al. ATIM-27. TUMOR MUTATIONAL BURDEN PREDICTS RESPONSE TO ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF TRANSCRIPTIONAL AND IMMUNOLOGICAL CORRELATES Neuro-Oncology. 21: vi7-vi7. DOI: 10.1093/Neuonc/Noz175.026 |
0.391 |
|
| 2019 |
Desjardins A, Randazzo D, Chandramohan V, Peters K, Johnson M, Threatt S, Bullock C, Jackman J, Healy P, Lipp E, Sampson J, Friedman A, Friedman H, Ashley D, Bigner D. ATIM-24. DOSE FINDING AND DOSE EXPANSION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG) Neuro-Oncology. 21: vi6-vi6. DOI: 10.1093/Neuonc/Noz175.023 |
0.378 |
|
| 2019 |
Peters K, Kirkpatrick J, Batinic-Haberle I, Affronti M, Woodring S, Iden D, Lipp E, Boyd K, Healy P, Herndon J, Spasojevic I, Penchev S, Gad S, Silberstein D, Johnson M, ... ... Friedman H, et al. First in Human Clinical Trial of a Metalloporphyrin Dual Radioprotectant and Radiosensitizer, BMX-001, in Newly Diagnosed High-Grade Glioma Undergoing Concurrent Chemoradiation International Journal of Radiation Oncology*Biology*Physics. 105: E106. DOI: 10.1016/J.Ijrobp.2019.06.2305 |
0.303 |
|
| 2019 |
Lee JWC, Johnson MO, Kirkpatrick JP, McSherry F, Herndon J, Lipp ES, Desjardins A, Randazzo D, Friedman HS, Ashley DM, Peters KB. Outcomes Following Adjuvant Radiation Therapy in Elderly Patients with Glioblastoma: A Retrospective Single Institution Analysis International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.2296 |
0.311 |
|
| 2018 |
Desjardins A, Gromeier M, Herndon JE, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, et al. Recurrent Glioblastoma Treated with Recombinant Poliovirus. The New England Journal of Medicine. PMID 29943666 DOI: 10.1056/Nejmoa1716435 |
0.446 |
|
| 2018 |
Affronti ML, Jackman JG, McSherry F, Herndon JE, Massey EC, Lipp E, Desjardins A, Friedman HS, Vlahovic G, Vredenburgh J, Peters KB. Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma. The Oncologist. PMID 29666296 DOI: 10.1634/Theoncologist.2018-0149 |
0.391 |
|
| 2018 |
Keir ST, Chandramohan V, Hemphill CD, Grandal MM, Melander MC, Pedersen MW, Horak ID, Kragh M, Desjardins A, Friedman HS, Bigner DD. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. Journal of Neuro-Oncology. PMID 29564747 DOI: 10.1007/S11060-018-2832-6 |
0.316 |
|
| 2018 |
Randazzo D, Kirkpatrick J, McSherry F, Herndon J, Affronti M, Johnson M, Vaslow Z, Lipp E, Desjardins A, Friedman H, Peters K. Qolp-13. Psychosocial Distress In Patients With Recurrent Meningiomas Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.899 |
0.344 |
|
| 2018 |
Peters K, Kirkpatrick J, Batinic-Haberle I, Affronti M, Woodring S, Iden D, Panta S, Lipp E, Healy P, Herndon J, Spasojevic I, Penchev S, Gad S, Siberstein D, Johnson M, ... ... Friedman H, et al. ACTR-28. PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS Neuro-Oncology. 20: vi17-vi17. DOI: 10.1093/Neuonc/Noy148.061 |
0.37 |
|
| 2018 |
Desjardins A, Randazzo D, Chandramohan V, Peters K, Johnson M, Thomas L, Threatt S, Bullock C, Herndon J, Boulton S, Healy P, Lipp E, Sampson J, Friedman A, Friedman H, et al. ATIM-36. DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG) Neuro-Oncology. 20: vi9-vi9. DOI: 10.1093/Neuonc/Noy148.031 |
0.316 |
|
| 2018 |
Ashley D, Desjardins A, Gromeier M, Muscat A, Herndon J, Friedman A, Friedman H, McSherry F, Randazzo D, Peters K, Threatt S, Bullock C, Miller E, Boulton S, Lipp E, et al. ATIM-27. INTRATUMORAL ADMINISTRATION OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF MUTATIONAL RESPONSE CORRELATES Neuro-Oncology. 20: vi7-vi7. DOI: 10.1093/Neuonc/Noy148.022 |
0.322 |
|
| 2018 |
Roskoski M, Gasinski D, Friedman H, Bigner D, Keir S. LGG-01. EVALUATION OF COBIMETINIB, A MEK INHIBITOR, IN LOW-GRADE PEDIATRIC BRAIN TUMORS Neuro-Oncology. 20: i104-i105. DOI: 10.1093/Neuonc/Noy059.345 |
0.351 |
|
| 2018 |
Gururangan S, Grant G, Driscoll T, Archer G, Herndon J, Friedman H, Kurtzberg J, Bigner D, Sampson J, Mitchell D. IMMU-27. Re-MATCH PROTOCOL: PHASE I STUDY OF AUTOLOGOUS TUMOR SPECIFIC LYMPHOCYTE TRANSFER (ALT) + DC VACCINE (DCV) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY (MAC) AND AUTOLOGOUS STEM CELL RESCUE (HDC + ASCR) OR NON-MYELOABLATIVE CHEMOTHERAPY (NMAC) IN PATIENTS WITH RECURRENT CENTRAL PNETs (r-PNET) Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy059.343 |
0.362 |
|
| 2017 |
Peters KB, Lipp ES, Miller E, Herndon JE, McSherry F, Desjardins A, Reardon DA, Friedman HS. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. Journal of Neuro-Oncology. PMID 29264836 DOI: 10.1007/S11060-017-2724-1 |
0.387 |
|
| 2017 |
Ghiaseddin A, Reardon D, Massey W, Mannerino A, Lipp ES, Herndon JE, McSherry F, Desjardins A, Randazzo D, Friedman HS, Peters KB. Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. The Oncologist. PMID 29133513 DOI: 10.1634/Theoncologist.2017-0501 |
0.405 |
|
| 2017 |
Waitkus MS, Pirozzi CJ, Moure CJ, Diplas BH, Hansen LJ, Carpenter AB, Yang R, Wang Z, Ingram BO, Karoly ED, Mohney RP, Spasojeic I, McLendon RE, Friedman HS, He Y, et al. Adaptive evolution of the GDH2 allosteric domain promotes gliomagenesis by resolving IDH1(R132H) induced metabolic liabilities. Cancer Research. PMID 29097607 DOI: 10.1158/0008-5472.Can-17-1352 |
0.3 |
|
| 2017 |
Reap E, Suryadevara CM, Batich KA, Sanchez-Perez L, Archer GE, Schmittling RJ, Norberg PK, Herndon JE, Healy P, Congdon KL, Gedeon PC, Campbell OC, Swartz AM, Riccione KA, Yi JS, ... ... Friedman HS, et al. Dendritic cells enhance polyfunctionality of adoptively transferred T cells which target cytomegalovirus in glioblastoma. Cancer Research. PMID 29093005 DOI: 10.1158/0008-5472.Can-17-0469 |
0.31 |
|
| 2017 |
Randazzo DM, McSherry F, Herndon JE, Affronti ML, Lipp ES, Flahiff C, Miller E, Woodring S, Freeman M, Healy P, Minchew J, Boulton S, Desjardins A, Vlahovic G, Friedman HS, et al. A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population. Journal of Neuro-Oncology. PMID 28669010 DOI: 10.1007/S11060-017-2535-4 |
0.363 |
|
| 2017 |
Batich KA, Reap EA, Archer GE, Sanchez-Perez L, Nair SK, Schmittling RJ, Norberg P, Xie W, Herndon JE, Healy P, McLendon RE, Friedman AH, Friedman HS, Bigner D, Vlahovic G, et al. Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 23: 1898-1909. PMID 28411277 DOI: 10.1158/1078-0432.Ccr-16-2057 |
0.404 |
|
| 2017 |
Affronti ML, Woodring S, Peters KB, Herndon JE, McSherry F, Healy PN, Desjardins A, Vredenburgh JJ, Friedman HS. A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab. Therapeutics and Clinical Risk Management. 13: 33-40. PMID 28096679 DOI: 10.2147/Tcrm.S122480 |
0.392 |
|
| 2017 |
Desjardins A, Sampson JH, Vlahovic G, Peters KB, Randazzo D, Threatt S, Herndon JE, Bullock CA, Miller ES, Boulton S, Lally-Goss D, McSherry F, Lipp ES, Friedman AH, Friedman HS, et al. Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG). Journal of Clinical Oncology. 35: e13533-e13533. DOI: 10.1200/Jco.2017.35.15_Suppl.E13533 |
0.399 |
|
| 2017 |
Peters KB, Affronti ML, Threatt S, Healy P, Herndon JE, Lipp ES, Panta S, Randazzo D, Friedman HS, Desjardins A. Pall-10. Increased Fatigue Associated With Tumor Progression In Newly Diagnosed Glioblastoma (Gbm) Patients Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.691 |
0.386 |
|
| 2017 |
Desjardins A, Randazzo D, Peters KB, Johnson MO, Massey W, Herndon JE, McSherry F, Lipp ES, Nadler P, Horak ID, Friedman HS. Actr-64. Phase 2 Study Of Sym004 For Adult Patients With Recurrent Glioblastoma (Gbm) Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.052 |
0.333 |
|
| 2016 |
Esbenshade AJ, Kocak M, Hershon L, Rousseau P, Decarie JC, Shaw S, Burger P, Friedman HS, Gajjar A, Moghrabi A. A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): A report from the Children's Oncology Group. Pediatric Blood & Cancer. PMID 28000417 DOI: 10.1002/Pbc.26373 |
0.306 |
|
| 2016 |
Kent CL, Mowery YM, Wright AO, Kim GJ, Desjardins A, Peters KB, Vlahovic G, Friedman HS, Cummings TJ, McLendon RE, Friedman AH, Sampson JH, Kirkpatrick JP. Long-Term Outcomes for Patients With Atypical or Malignant Meningiomas Treated With Radiation Therapy: A Single-Institution Retrospective Analysis. International Journal of Radiation Oncology, Biology, Physics. 96: E83-E84. PMID 27675478 DOI: 10.1016/J.Ijrobp.2016.06.802 |
0.308 |
|
| 2016 |
Affronti ML, Woodring S, Allen K, Kirkpatrick J, Peters KB, Herndon JE, McSherry F, Healy PN, Desjardins A, Vredenburgh JJ, Friedman HS. Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ). Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 27271867 DOI: 10.1007/S00520-016-3276-1 |
0.394 |
|
| 2016 |
Desjardins A, Sampson JH, Peters KB, Vlahovic G, Randazzo D, Threatt S, Herndon JE, Boulton S, Lally-Goss D, McSherry F, Lipp ES, Friedman AH, Friedman HS, Bigner DD, Gromeier M. Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls. Journal of Clinical Oncology. 34: 2061-2061. DOI: 10.1200/Jco.2016.34.15_Suppl.2061 |
0.443 |
|
| 2016 |
Peters KB, Woodring S, Healy P, Herndon JE, Lipp ES, Minchew J, Zalutsky B, Affronti M, Randazzo D, Desjardins A, Vlahovic G, Friedman HS. Baseline cognitive function to predict survival in patients with glioblastoma. Journal of Clinical Oncology. 34: 10125-10125. DOI: 10.1200/Jco.2016.34.15_Suppl.10125 |
0.358 |
|
| 2016 |
Randazzo D, McSherry F, Herndon J, Affronti ML, Lipp E, Flahiff C, Miller E, Woodring S, Freeman M, Healy P, Minchew J, Boulton S, Desjardins A, Vlahovic G, Friedman H, et al. Qlif-20. A Cross-Sectional Study Of Distress Throughout The Disease Trajectory In Primary Brain Tumor Patients Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.664 |
0.338 |
|
| 2016 |
Desjardins A, Randazzo D, Chandramohan V, Sampson J, Peters K, Vlahovic G, Threatt S, Herndon J, Boulton S, Lally-Goss D, Healy P, Lipp E, Friedman A, Friedman H, Bigner D. ATIM-18. PHASE I DOSE ESCALATION STUDY OF D2C7-IT ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG) Neuro-Oncology. 18: vi21-vi22. DOI: 10.1093/Neuonc/Now212.083 |
0.341 |
|
| 2015 |
Okamura T, Antoun G, Keir ST, Friedman H, Bigner DD, Ali-Osman F. Phosphorylation of GSTP1 by EGFR Promotes Formation of the Inhibitory GSTP1-JNK Complex and Suppresses JNK Downstream Signaling and Apoptosis in Brain Tumor Cells. The Journal of Biological Chemistry. PMID 26429914 DOI: 10.1074/Jbc.M115.656140 |
0.323 |
|
| 2015 |
Peters KB, Lou E, Desjardins A, Reardon DA, Lipp ES, Miller E, Herndon JE, McSherry F, Friedman HS, Vredenburgh JJ. Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma. The Oncologist. PMID 26025933 DOI: 10.1634/Theoncologist.2015-0135 |
0.389 |
|
| 2015 |
Flores C, Pham C, Snyder D, Yang S, Sanchez-Perez L, Sayour E, Cui X, Kemeny H, Friedman H, Bigner DD, Sampson J, Mitchell DA. Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas. Oncoimmunology. 4: e994374. PMID 25949916 DOI: 10.4161/2162402X.2014.994374 |
0.366 |
|
| 2015 |
Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE, Coan A, McLendon RE, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 519: 366-9. PMID 25762141 DOI: 10.1038/Nature14320 |
0.305 |
|
| 2015 |
McLendon RE, Lipp E, Satterfield D, Ehinger M, Austin A, Fleming D, Perkinson K, Lefaivre M, Zagzag D, Wiener B, Gururangan S, Fuchs H, Friedman HS, Herndon JE, Healy P. Prognostic marker analysis in pediatric intracranial ependymomas. Journal of Neuro-Oncology. 122: 255-61. PMID 25563815 DOI: 10.1007/S11060-014-1711-Z |
0.309 |
|
| 2015 |
Mitchell DA, Sayour EJ, Reap E, Schmittling R, DeLeon G, Norberg P, Desjardins A, Friedman AH, Friedman HS, Archer G, Sampson JH. Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide. Cancer Immunology Research. 3: 320-5. PMID 25387895 DOI: 10.1158/2326-6066.Cir-14-0100 |
0.316 |
|
| 2015 |
Kim J, Woodring S, Affronti ML, Randazzo D, McSherry F, Herndon JE, Lipp ES, Desjardins A, Vlahovic G, Friedman HS, Peters KB. Secondary cancers in long-term survivors of primary glioblastoma. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E20616 |
0.33 |
|
| 2015 |
Friedman HS, Peters KB, Vlahovic G, Randazzo D, Boulton S, Woodring S, Lipp ES, Herndon JE, Healy P, Miller E, Karmali RA, Desjardins A. Phase 1 clinical trial of carboxyamidotriazole orotate (CTO) in combination with lomustine (CCNU) for adult patients with recurrent malignant glioma (MG). Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E13004 |
0.371 |
|
| 2015 |
Randazzo DM, McSherry F, Herndon JE, Affronti ML, Lipp ES, Flahiff C, Miller E, Woodring S, Freeman M, Healy P, Minchew J, Boulton S, Desjardins A, Vlahovic G, Friedman HS, et al. Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients. Journal of Clinical Oncology. 33: 9553-9553. DOI: 10.1200/Jco.2015.33.15_Suppl.9553 |
0.361 |
|
| 2015 |
Desjardins A, Peters KB, Vlahovic G, Randazzo D, Boulton S, Massey WC, Lipp ES, Herndon JE, Healy P, Miller E, Karmali RA, Friedman HS. Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1. Journal of Clinical Oncology. 33: 2067-2067. DOI: 10.1200/Jco.2015.33.15_Suppl.2067 |
0.407 |
|
| 2015 |
Ghiaseddin A, Reardon DA, Massey W, Mannerino A, Lipp ES, Herndon JE, McSherry F, Desjardins A, Randazzo DM, Vlahovic G, Friedman HS, Peters KB. Phase II study of bevacizumab and vorinostat for recurrent glioblastoma. Journal of Clinical Oncology. 33: 2034-2034. DOI: 10.1200/Jco.2015.33.15_Suppl.2034 |
0.361 |
|
| 2015 |
Keir ST, Rasheed BA, Hoadley KA, Roskoski MA, Gasinski D, Kwatra MM, Friedman HS, Bigner DD. Abstract 2435A: Identification and treatment data of xenografts representing TCGA-defined glioblastoma subtypes Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-2435A |
0.359 |
|
| 2015 |
Boyle J, McSherry F, Herndon J, Desjardins A, Sampson J, Peters K, Chino J, Allen K, Cabrera A, Kim G, Friedman H, Kirkpatrick J. Rtrb-04Stereotactic Radiosurgery For Recurrent High-Grade Gliomas: Patient Selection And The Role Of Bevacizumab Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov231.04 |
0.373 |
|
| 2015 |
Randazzo DM, McSherry F, Herndon JE, Affronti ML, Lipp ES, Flahiff C, Miller E, Woodring S, Freeman M, Healey P, Minchew J, Boulton S, Desjardins A, Vlahovic G, Friedman HS, et al. QOL-21DIET AND HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN THE PRIMARY BRAIN TUMOR POPULATION Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov230.21 |
0.34 |
|
| 2015 |
Peters K, Affronti M, Woodring S, Lipp E, Healy P, McSherry F, Herndon J, Flahiff C, Miller E, Freeman M, Minchew J, Zalutsky B, Taylor B, Boulton S, Randazzo D, ... ... Friedman H, et al. QOL-20LOW-DOSE NALTREXONE IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA: PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED PILOT STUDY Neuro-Oncology. 17: v192.2-v192. DOI: 10.1093/Neuonc/Nov230.20 |
0.357 |
|
| 2015 |
Ghiaseddin A, West M, Hornsby W, Freeman M, Lipp E, McSherry F, Herndon J, Desjardins A, Friedman H, Jones L, Peters K. Qol-19Prospective Evaluation Of Cardiopulmonary Fitness In Newly Diagnosed Glioblastoma Patients Receiving An Anti-Angiogenic Regimen Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov230.19 |
0.379 |
|
| 2015 |
Weant M, Dunn-Pirio A, Peters K, Vlahovic G, Randazzo D, Herndon J, Healy P, Threatt S, Sampson J, Friedman A, Friedman H, Desjardins A. Atct-13Bevacizumab, Radiation Therapy (Rt) And Temozolomide Followed By Bevacizumab And Temozolomide With Continuation Of Bevacizumab Beyond Progression: A Phase Ii Trial Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov206.13 |
0.389 |
|
| 2015 |
Affronti ML, Friedman HS, Desjardins A, Vlahovic G, Randazzo DM, Herndon JE, McSherry F, Lipp ES, Mannerico A, Massey W, Miller E, Iden D, Peters KB. Atct-01Phase Ii Study To Evaluate The Efficacy And Safety Of Rilotumumab And Bevacizumab (Bev) In Subjects With Recurrent Malignant Glioma (Mg) Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov206.01 |
0.435 |
|
| 2015 |
Mowery Y, Kim G, Wright A, Desjardins A, Peters K, Vlahovic G, Friedman H, Sampson J, Kirkpatrick J. Outcomes for Patients With Intracranial Meningiomas Treated With Radiation therapy and Bevacizumab: A Single-Institution Retrospective Analysis International Journal of Radiation Oncology*Biology*Physics. 93: E104. DOI: 10.1016/J.Ijrobp.2015.07.813 |
0.319 |
|
| 2014 |
Di K, Keir ST, Alexandru-Abrams D, Gong X, Nguyen H, Friedman HS, Bota DA. Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models. Journal of Neuro-Oncology. 120: 473-81. PMID 25115740 DOI: 10.1007/S11060-014-1579-Y |
0.339 |
|
| 2014 |
Peters KB, West MJ, Hornsby WE, Waner E, Coan AD, McSherry F, Herndon JE, Friedman HS, Desjardins A, Jones LW. Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients. Journal of Neuro-Oncology. 120: 499-506. PMID 25115739 DOI: 10.1007/S11060-014-1574-3 |
0.354 |
|
| 2014 |
Desjardins A, Friedman HS. Bevacizumab therapy for glioblastoma: a passionate discussion. Cns Oncology. 3: 1-3. PMID 25054891 DOI: 10.2217/Cns.13.53 |
0.395 |
|
| 2014 |
Brown MC, Dobrikova EY, Dobrikov MI, Walton RW, Gemberling SL, Nair SK, Desjardins A, Sampson JH, Friedman HS, Friedman AH, Tyler DS, Bigner DD, Gromeier M. Oncolytic polio virotherapy of cancer. Cancer. 120: 3277-86. PMID 24939611 DOI: 10.1002/Cncr.28862 |
0.306 |
|
| 2014 |
Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, Zhu H, Wang CY, Carpenter AB, Friedman H, Friedman AH, et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget. 5: 1515-25. PMID 24722048 DOI: 10.18632/Oncotarget.1765 |
0.336 |
|
| 2014 |
Gururangan S, Fangusaro J, Poussaint TY, McLendon RE, Onar-Thomas A, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Fahey F, Vajapeyam S, Jakacki R, Gajjar A, Goldman S, Pollack IF, ... Friedman HS, et al. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. Neuro-Oncology. 16: 310-7. PMID 24311632 DOI: 10.1093/Neuonc/Not154 |
0.46 |
|
| 2014 |
Killela PJ, Pirozzi CJ, Reitman ZJ, Jones S, Rasheed BA, Lipp E, Friedman H, Friedman AH, He Y, McLendon RE, Bigner DD, Yan H. The genetic landscape of anaplastic astrocytoma. Oncotarget. 5: 1452-7. PMID 24140581 DOI: 10.18632/Oncotarget.1505 |
0.302 |
|
| 2014 |
Sampson JH, Vlahovic G, Desjardins A, Friedman HS, Baehring JM, Hafler D, Rollin L, Coric V, Perez SN, Reardon DA. Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM). Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps2101 |
0.41 |
|
| 2014 |
Peters KB, Woodring S, Affronti ML, McSherry F, Herndon JE, Desjardins A, Ranjan T, Vlahovic G, Friedman AH, Friedman HS. Long-term survivorship in adult primary glioblastoma: Clinical and neurological outcomes of a large, single-center study. Journal of Clinical Oncology. 32: 9519-9519. DOI: 10.1200/Jco.2014.32.15_Suppl.9519 |
0.391 |
|
| 2014 |
Vlahovic G, Archer GE, Lally-Goss D, Norman S, Desjardins A, Peters KB, Ranjan T, Watts J, Healy P, Herndon JE, Friedman HS, Friedman AH, Bigner DD, Sampson JH. Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology. 32: 3069-3069. DOI: 10.1200/Jco.2014.32.15_Suppl.3069 |
0.384 |
|
| 2014 |
Friedman HS, Herndon JE, McSherry F, Ravelo A, Lipp ES, Healy P, Peters KB, Ranjan T, Vlahovic G, Watts J, Sampson JH, Friedman AH, Desjardins A. Single-institution retrospective review of newly diagnosed glioblastoma (GBM) patients (pts) treated on bevacizumab (BEV) in clinical practice. Journal of Clinical Oncology. 32: 2082-2082. DOI: 10.1200/Jco.2014.32.15_Suppl.2082 |
0.348 |
|
| 2014 |
Desjardins A, Sampson JH, Peters KB, Ranjan T, Vlahovic G, Threatt S, Herndon JE, Boulton S, Lally-Goss D, McSherry F, Friedman A, Friedman HS, Bigner DD, Gromeier M. Abstract CT416: Intratumoral administration of an Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) in recurrent glioblastoma (GBM): Preliminary results of the Phase I clinical trial Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct416 |
0.407 |
|
| 2014 |
Keir ST, Rasheed BA, Hoadley KA, Roskoski MA, Gasinski D, Killela PJ, Yan H, Kwatra MM, Friedman HS, Bigner DD. Abstract 838: Establishment, identification and treatment data of TCGA glioblatoma xenograft subtypes Cancer Research. 74: 838-838. DOI: 10.1158/1538-7445.Am2014-838 |
0.338 |
|
| 2014 |
Randazzo D, Affronti M, Lipp E, McSherry F, Herndon J, Flahiff C, Miller E, Woodring S, Freeman M, Healy P, Minchew J, Boulton S, Desjardins A, Ranjan T, Vlahovic G, ... Friedman H, et al. Ql-21Spiritual Well-Being And Its Association With Health-Related Quality Of Life In Primary Brain Tumor Patients Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou269.20 |
0.347 |
|
| 2014 |
Peters K, Randazzo D, Affronti M, Lipp E, McSherry F, Herndon J, Flahiff C, Miller E, Woodring S, Freeman M, Healy P, Minchew J, Boulton S, Desjardins A, Ranjan T, ... ... Friedman H, et al. Ql-20Prognostic Importance Of Health-Related Quality Of Life And Fatigue In Newly Diagnosed Glioblastoma Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou269.19 |
0.335 |
|
| 2014 |
Mowery Y, Wright A, Desjardins A, Peters K, Ranjan T, Vlahovic G, Friedman H, Zomorodi A, Kaylie D, Adogwa O, Nimjee S, Sperduto W, Chagoya G, Fatemi P, McLendon R, et al. MS-19 * LONG-TERM OUTCOMES FOR PATIENTS WITH INTRACRANIAL MENINGIOMAS: A SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS Neuro-Oncology. 16: v130-v131. DOI: 10.1093/Neuonc/Nou260.18 |
0.409 |
|
| 2014 |
Flores C, Pham C, Snyder D, Yang S, Sanchez-Perez L, Sayour E, Cui X, Kemeny H, Friedman H, Bigner D, Sampson J, Mitchell D. IT-10 * SYNERGISTIC CELLULAR INTERACTIONS IN ADOPTIVE IMMUNOTHERAPY LEADS TO IMMUNOLOGIC REJECTION OF MALIGNANT GLIOMA Neuro-Oncology. 16: v111-v111. DOI: 10.1093/Neuonc/Nou258.8 |
0.377 |
|
| 2014 |
Vlahovic G, Archer G, Lally-Goss D, Reap E, Batich K, Desjardins A, Peters K, Ranjan T, Healy P, Herndon J, Friedman A, Friedman H, Bigner D, Sampson J. IT-34 * PILOT STUDY OF COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) Neuro-Oncology. 16: v117-v117. DOI: 10.1093/Neuonc/Nou258.32 |
0.337 |
|
| 2014 |
Keir S, Roskoski M, Gasinski D, Friedman H, Bigner D. ET-28 * COMBINATION THERAPY WITH MET TYROSINE KINASE INHIBITOR EMD1214063 AND BEVACIZUMAB Neuro-Oncology. 16: v85-v85. DOI: 10.1093/Neuonc/Nou255.28 |
0.374 |
|
| 2014 |
Ranjan T, Peters kB, Vlahovic G, Watts J, Dutton S, Boulton S, Lipp E, Herndon J, Healy P, Miller E, Friedman H, Karmali R, Desjardins A. At-48A Phase 1 Trial Of Carboxyamidotriazole Orotate (Cto) In Combination With Bevacizumab For Adult Patients With Recurrent Malignant Glioma Post-Bevacizumab Failure Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.47 |
0.437 |
|
| 2014 |
Peters K, Reardon D, Randazzo D, Dutton S, Edwards A, Lipp E, Herndon J, McSherry F, Desjardins A, Ranjan T, Vlahovic G, Friedman H. At-46Vorinostat And Bevacizumab For Recurrent High-Grade Glioma: Interim Analysis Of A Phase Ii Clinical Trial Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.45 |
0.436 |
|
| 2014 |
Ghiaseddin A, Dunn-Pirio A, Peters K, Vlahovic G, Herndon J, Threatt S, Sampson J, Friedman A, Friedman H, Desjardins A. At-22Phase Ii Trial Of Bevacizumab, Radiation Therapy (Rt) And Temozolomide Followed By Bevacizumab And Temozolomide With Continuation Of Bevacizumab Beyond Progression Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.22 |
0.396 |
|
| 2014 |
Desjardins A, Sampson J, Peters K, Vlahovic G, Threatt S, Herndon J, Boulton S, Lally-Goss D, McSherry F, Lipp E, Friedman A, Friedman H, Bigner D, Gromeier M. AT-21 * FINAL RESULTS OF A PHASE 1 TRIAL OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) AGAINST RECURRENT GLIOBLASTOMA (GBM) Neuro-Oncology. 16: v13-v13. DOI: 10.1093/Neuonc/Nou237.21 |
0.384 |
|
| 2014 |
Desjardins A, Herndon J, McSherry F, Ravelo A, Lipp E, Healy P, Peters K, Vlahovic G, Sampson J, Friedman A, Friedman H. At-20Single Institution Retrospective Review Of Performance Status And Corticosteroid Use In Newly Diagnosed Glioblastoma (Gbm) Patients (Pts) Treated On Bevacizumab (Bev) Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.20 |
0.353 |
|
| 2014 |
Desjardins A, Herndon J, McSherry F, Ravelo A, Lipp E, Healy P, Boulton S, Peters K, Vlahovic G, Sampson J, Friedman A, Friedman H. At-19Single Institution Retrospective Comparison Of Glioblastoma (Gbm) Patients (Pts) Initiated On Bevacizumab (Bev) Before Versus After Recurrence In Clinical Practice Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.19 |
0.313 |
|
| 2014 |
Desjardins A, Sampson JH, Peters KB, Ranjan T, Vlahovic G, Threatt S, Herndon JE, Boulton S, Lally-Goss D, McSherry F, Friedman AH, Friedman HS, Bigner DD, Gromeier M. ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN RECURRENT GLIOBLASTOMA (GBM): FIRST PHASE I CLINICAL TRIAL EVALUATING THE INTRATUMORAL ADMINISTRATION Neuro-Oncology. 16: iii43-iii43. DOI: 10.1093/Neuonc/Nou209.5 |
0.418 |
|
| 2014 |
Gromeier M, Dobrikova E, Dobrikov M, Brown M, Bryant J, Threatt S, Boulton S, Carter K, Herndon J, Desjardins A, Friedman H, Sampson J, Friedman A, Bigner D. ONCOLYTIC POLIOVIRUS IMMUNOTHERAPY OF GLIOBLASTOMA Neuro-Oncology. 16: iii41-iii41. DOI: 10.1093/Neuonc/Nou208.69 |
0.35 |
|
| 2014 |
Keir ST, Roskoski MA, Gasinski D, Kwatra MK, Friedman HS, Bigner DD. IDENTIFICATION AND PRELIMINARY TREATMENT DATA OF XENOGRAFTS REPRESENTING TCGA-DEFINED SUBTYPES Neuro-Oncology. 16: iii35-iii35. DOI: 10.1093/Neuonc/Nou208.45 |
0.371 |
|
| 2013 |
Fangusaro J, Gururangan S, Poussaint TY, McLendon RE, Onar-Thomas A, Warren KE, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, et al. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). Cancer. 119: 4180-7. PMID 24104527 DOI: 10.1002/Cncr.28343 |
0.45 |
|
| 2013 |
Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. Journal of Neurosurgery. 119: 1415-23. PMID 24093630 DOI: 10.3171/2013.7.Jns1323 |
0.324 |
|
| 2013 |
Tarbell NJ, Friedman H, Polkinghorn WR, Yock T, Zhou T, Chen Z, Burger P, Barnes P, Kun L. High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2936-41. PMID 23857975 DOI: 10.1200/Jco.2012.43.9984 |
0.362 |
|
| 2013 |
Cabrera AR, Cuneo KC, Desjardins A, Sampson JH, McSherry F, Herndon JE, Peters KB, Allen K, Hoang JK, Chang Z, Craciunescu O, Vredenburgh JJ, Friedman HS, Kirkpatrick JP. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. International Journal of Radiation Oncology, Biology, Physics. 86: 873-9. PMID 23725997 DOI: 10.1016/J.Ijrobp.2013.04.029 |
0.44 |
|
| 2013 |
Jiang X, Reardon DA, Desjardins A, Vredenburgh JJ, Quinn JA, Austin AD, Herndon JE, McLendon RE, Friedman HS. O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma. Journal of Neuro-Oncology. 114: 135-40. PMID 23686298 DOI: 10.1007/S11060-013-1162-Y |
0.382 |
|
| 2013 |
Lou E, Peters KB, Sumrall AL, Desjardins A, Reardon DA, Lipp ES, Herndon JE, Coan A, Bailey L, Turner S, Friedman HS, Vredenburgh JJ. Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. Cancer Medicine. 2: 185-95. PMID 23634286 DOI: 10.1002/Cam4.58 |
0.455 |
|
| 2013 |
Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America. 110: 6021-6. PMID 23530248 DOI: 10.1093/Neuonc/Nou206.18 |
0.345 |
|
| 2013 |
Keir ST, Friedman HS, Reardon DA, Bigner DD, Gray LA. Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model. Journal of Neuro-Oncology. 111: 97-102. PMID 23086436 DOI: 10.1007/S11060-012-0995-0 |
0.32 |
|
| 2013 |
Ranjan T, Peters KB, Vlahovic G, Alderson LM, Herndon JE, McSherry F, Threatt S, Sampson JH, Friedman AH, Bigner DD, Friedman HS, Vredenburgh JJ, Desjardins A. Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT. Journal of Clinical Oncology. 31: e13015-e13015. DOI: 10.1200/Jco.2013.31.15_Suppl.E13015 |
0.387 |
|
| 2013 |
Sampson JH, Desjardins A, Peters KB, Ranjan T, Vlahovic G, Lally-Goss D, Threatt S, Herndon J, Friedman AH, Friedman H, Bigner D, Gromeier M. 107 Dose-Finding and Safety Study of an Oncolytic Polio/Rhinovirus Recombinant Against Recurrent Glioblastoma Neurosurgery. 60: 155. DOI: 10.1200/Jco.2013.31.15_Suppl.2094 |
0.393 |
|
| 2013 |
Lindhorst SM, McSherry F, Desjardins A, Friedman HS, Peters KB. Analysis of high-dose methotrexate with rituximab versus other treatment regimens for primary central nervous system (CNS) lymphoma. Journal of Clinical Oncology. 31: 2090-2090. DOI: 10.1200/Jco.2013.31.15_Suppl.2090 |
0.342 |
|
| 2013 |
Keir ST, Roskoski MA, Kragh M, Pederson MW, Jacobsen HJ, Horak ID, Friedman HS, Bigner DD. Abstract 4322: Efficacy of Sym004, a novel anti-EGFR antibody mixture, against EGFRvIII positive glioblastoma xenografts. Cancer Research. 73: 4322-4322. DOI: 10.1158/1538-7445.Am2013-4322 |
0.371 |
|
| 2013 |
Keir ST, Roskoski MA, Wagner S, Tiedt R, Bigner DD, Friedman HS. Abstract 2079: Antitumoral activity of INC280 against adult glioblastoma brain tumors xenografts. Cancer Research. 73: 2079-2079. DOI: 10.1158/1538-7445.Am2013-2079 |
0.374 |
|
| 2012 |
Reardon DA, Herndon JE, Peters KB, Desjardins A, Coan A, Lou E, Sumrall AL, Turner S, Lipp ES, Sathornsumetee S, Rich JN, Sampson JH, Friedman AH, Boulton ST, Bigner DD, ... Friedman HS, et al. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. British Journal of Cancer. 107: 1481-7. PMID 23037712 DOI: 10.1038/Bjc.2012.415 |
0.407 |
|
| 2012 |
Gururangan S, Fangusaro J, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Gajjar A, Goldman S, Friedman HS, Packer RJ, Boyett JM, Kun LE, McLendon R. Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. Neuro-Oncology. 14: 1404-12. PMID 23019233 DOI: 10.1093/Neuonc/Nos213 |
0.452 |
|
| 2012 |
Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, ... ... Friedman H, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 3: 709-22. PMID 22869205 DOI: 10.18632/Oncotarget.588 |
0.366 |
|
| 2012 |
Lou E, Sumrall AL, Turner S, Peters KB, Desjardins A, Vredenburgh JJ, McLendon RE, Herndon JE, McSherry F, Norfleet J, Friedman HS, Reardon DA. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. Journal of Neuro-Oncology. 109: 63-70. PMID 22535433 DOI: 10.1007/S11060-012-0861-0 |
0.458 |
|
| 2012 |
Reardon DA, Vredenburgh JJ, Desjardins A, Peters KB, Sathornsumetee S, Threatt S, Sampson JH, Herndon JE, Coan A, McSherry F, Rich JN, McLendon RE, Zhang S, Friedman HS. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. Journal of Neuro-Oncology. 108: 499-506. PMID 22407177 DOI: 10.1007/S11060-012-0848-X |
0.418 |
|
| 2012 |
Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemotherapy and Pharmacology. 69: 1507-18. PMID 22392572 DOI: 10.1007/S00280-012-1854-6 |
0.407 |
|
| 2012 |
Reardon DA, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Gururangan S, Peters KB, McLendon R, Sathornsumetee S, Rich JN, Lipp ES, Janney D, Friedman HS. Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer. 118: 4759-67. PMID 22371319 DOI: 10.1002/Cncr.26541 |
0.383 |
|
| 2012 |
Reardon DA, Herndon JE, Peters K, Desjardins A, Coan A, Lou E, Sumrall A, Turner S, Sathornsumetee S, Rich JN, Boulton S, Lipp ES, Friedman HS, Vredenburgh JJ. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. Journal of Neuro-Oncology. 107: 213-21. PMID 21997879 DOI: 10.1007/S11060-011-0740-0 |
0.406 |
|
| 2012 |
Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. Journal of Neuro-Oncology. 107: 155-64. PMID 21986722 DOI: 10.1007/S11060-011-0722-2 |
0.461 |
|
| 2012 |
Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. Journal of Neuro-Oncology. 106: 409-15. PMID 21938530 DOI: 10.1007/S11060-011-0687-1 |
0.468 |
|
| 2012 |
Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE, Bailey L, Peters KB, Friedman HS, Vredenburgh JJ. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer. 118: 1302-12. PMID 21792866 DOI: 10.1002/Cncr.26381 |
0.435 |
|
| 2012 |
Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, Friedman HS, Willett CG, Kirkpatrick JP. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. International Journal of Radiation Oncology, Biology, Physics. 82: 2018-24. PMID 21489708 DOI: 10.1016/J.Ijrobp.2010.12.074 |
0.439 |
|
| 2012 |
Paldino MJ, Desjardins A, Friedman HS, Vredenburgh JJ, Barboriak DP. A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme. The British Journal of Radiology. 85: 382-9. PMID 21224297 DOI: 10.1259/Bjr/24774491 |
0.328 |
|
| 2012 |
Vredenburgh JJ, Desjardins A, Kirkpatrick JP, Reardon DA, Peters KB, Herndon JE, Marcello J, Bailey L, Threatt S, Sampson J, Friedman A, Friedman HS. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. International Journal of Radiation Oncology, Biology, Physics. 82: 58-66. PMID 21036490 DOI: 10.1016/J.Ijrobp.2010.08.058 |
0.305 |
|
| 2012 |
Friedman HS, Brandes AA. CNS Oncology: reflecting a rapidly changing landscape Cns Oncology. 1: 1-2. DOI: 10.2217/Cns.12.7 |
0.367 |
|
| 2012 |
Desjardins A, Vredenburgh JJ, Peters KB, Threatt S, Herndon JE, Sampson JH, Friedman AH, Friedman HS, Reardon DA. Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure. Journal of Clinical Oncology. 30: 2095-2095. DOI: 10.1200/Jco.2012.30.15_Suppl.2095 |
0.471 |
|
| 2012 |
Vredenburgh JJ, Desjardins A, Peters KB, Reardon DA, Herndon JE, Coan AD, Kirkpatrick J, Bailey L, Threatt S, Sampson JH, Friedman AH, Friedman HS. Safety and efficacy of the addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma multiforme. Journal of Clinical Oncology. 30: 2094-2094. DOI: 10.1200/Jco.2012.30.15_Suppl.2094 |
0.376 |
|
| 2012 |
Friedman HS, Desjardins A, Peters KB, Reardon DA, Kirkpatrick J, Herndon JE, Coan AD, Bailey L, Sampson JH, Friedman AH, Vredenburgh JJ. The addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology. 30: 2090-2090. DOI: 10.1200/Jco.2012.30.15_Suppl.2090 |
0.37 |
|
| 2012 |
Affronti ML, Desjardins A, Friedman HS, Peters KB, Herndon JE, McSherry F, Lipp ES, Brickhouse A, Massey WC, Miller E, Cheshire S, Cone C, Kalinowski KH, Kim J, Lay HH, et al. Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG). Journal of Clinical Oncology. 30: 2074-2074. DOI: 10.1200/Jco.2012.30.15_Suppl.2074 |
0.365 |
|
| 2012 |
Peters KB, Vredenburgh JJ, Desjardins A, Friedman HS, Herndon JE, Coan AD, McSherry F, Lipp ES, Brickhouse A, Massey WC, Reardon DA. Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial. Journal of Clinical Oncology. 30: 2027-2027. DOI: 10.1200/Jco.2012.30.15_Suppl.2027 |
0.422 |
|
| 2012 |
Keir ST, Gray L, Friedman HS. Abstract LB-76: Mibefradil, a novel therapy for glioblastoma: An interlaced therapy approach Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-76 |
0.377 |
|
| 2012 |
Antoun GR, McLendon R, Friedman H, Friedman A, Bigner D, Ali-Osman F. Abstract 1177: The mutational status of the p53 tumor suppressor gene is a determinant of GSTP1 expression and mediates GSTP1-dependent drug resistance in human glioblastoma Cancer Research. 72: 1177-1177. DOI: 10.1158/1538-7445.Am2012-1177 |
0.329 |
|
| 2011 |
Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Coan AD, Herndon JE, Friedman HS. Bevacizumab (BV) continuation following BV progression: Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2030. PMID 28023816 DOI: 10.1200/Jco.2011.29.15_Suppl.2030 |
0.393 |
|
| 2011 |
Sumrall AL, Reardon DA, Desjardins A, Peters K, Lou E, Turner SG, Bailey L, Friedman HS, Vredenburgh JJ. Venous thromboembolic complications in patients with malignant glioma treated on a bevacizumab clinical trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 9090. PMID 28021530 DOI: 10.1200/Jco.2011.29.15_Suppl.9090 |
0.396 |
|
| 2011 |
Bota DA, Eroglu Z, Reardon DA, Fu BD, Norfleet J, Desjardins A, Linskey ME, Peters K, Friedman HS, Vredenburgh JJ. Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2056. PMID 28019947 DOI: 10.1200/Jco.2011.29.15_Suppl.2056 |
0.384 |
|
| 2011 |
Lou E, Reardon DA, Peters K, Desjardins A, Herndon JE, Coan AD, Turner SG, Sumrall AL, Bailey L, Friedman HS, Vredenburgh JJ. Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2055. PMID 28019946 DOI: 10.1200/Jco.2011.29.15_Suppl.2055 |
0.415 |
|
| 2011 |
Desjardins A, Reardon DA, Vredenburgh JJ, Peters K, Trikha M, James J, Gardner M, Brickhouse A, Herndon JE, Friedman HS. A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2070. PMID 28019891 DOI: 10.1200/Jco.2011.29.15_Suppl.2070 |
0.363 |
|
| 2011 |
Vredenburgh JJ, Desjardins A, Reardon DA, Peters K, Kirkpatrick J, Coan AD, Bailey L, Janney D, Lu C, Friedman HS. Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly-diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2098. PMID 28019863 DOI: 10.1200/Jco.2011.29.15_Suppl.2098 |
0.345 |
|
| 2011 |
Turner SG, Peters KB, Vredenburgh JJ, Desjardins A, Friedman HS, Reardon DA. Everolimus tablets for patients with subependymal giant cell astrocytoma. Expert Opinion On Pharmacotherapy. 12: 2265-9. PMID 21806479 DOI: 10.1517/14656566.2011.601742 |
0.367 |
|
| 2011 |
Reardon DA, Vredenburgh JJ, Coan A, Desjardins A, Peters KB, Gururangan S, Sathornsumetee S, Rich JN, Herndon JE, Friedman HS. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. Journal of Neuro-Oncology. 105: 621-7. PMID 21744079 DOI: 10.1007/S11060-011-0631-4 |
0.458 |
|
| 2011 |
Desjardins A, Reardon DA, Peters KB, Threatt S, Coan AD, Herndon JE, Friedman AH, Friedman HS, Vredenburgh JJ. A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. Journal of Neuro-Oncology. 105: 601-6. PMID 21735117 DOI: 10.1007/S11060-011-0627-0 |
0.396 |
|
| 2011 |
Ruden E, Reardon DA, Coan AD, Herndon JE, Hornsby WE, West M, Fels DR, Desjardins A, Vredenburgh JJ, Waner E, Friedman AH, Friedman HS, Peters KB, Jones LW. Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2918-23. PMID 21690470 DOI: 10.1200/Jco.2011.34.9852 |
0.308 |
|
| 2011 |
Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Coan A, Threatt S, Friedman AH, Friedman HS. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer. 117: 5351-8. PMID 21590689 DOI: 10.1002/Cncr.26188 |
0.439 |
|
| 2011 |
Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, ... Friedman HS, et al. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 13: 660-8. PMID 21558074 DOI: 10.1093/Neuonc/Nor024 |
0.396 |
|
| 2011 |
Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, Friedman AH, Bigner DD, Friedman HS. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4119-24. PMID 21531816 DOI: 10.1158/1078-0432.Ccr-11-0120 |
0.397 |
|
| 2011 |
Reardon DA, Turner S, Peters KB, Desjardins A, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Jones LW, Kirkpatrick JP, Friedman AH, Vredenburgh JJ, Bigner DD, Friedman HS. A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. Journal of the National Comprehensive Cancer Network : Jnccn. 9: 414-27. PMID 21464146 DOI: 10.6004/Jnccn.2011.0038 |
0.415 |
|
| 2011 |
Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, Boca SM, Carter H, Samayoa J, Bettegowda C, Gallia GL, Jallo GI, Binder ZA, Nikolsky Y, Hartigan J, ... ... Friedman HS, et al. The genetic landscape of the childhood cancer medulloblastoma. Science (New York, N.Y.). 331: 435-9. PMID 21163964 DOI: 10.1126/Science.1198056 |
0.312 |
|
| 2011 |
Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology. 13: 324-33. PMID 21149254 DOI: 10.1093/Neuonc/Noq157 |
0.433 |
|
| 2011 |
Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 13: 143-51. PMID 21084434 DOI: 10.1093/Neuonc/Noq151 |
0.39 |
|
| 2011 |
Reardon DA, Desjardins A, Peters K, Gururangan S, Sampson J, Rich JN, McLendon R, Herndon JE, Marcello J, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Journal of Neuro-Oncology. 103: 371-9. PMID 20853132 DOI: 10.1007/S11060-010-0403-6 |
0.456 |
|
| 2011 |
Peters KB, Coyle TE, Vredenburgh JJ, Desjardins A, Friedman HS, Reardon DA. Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy. Journal of Neuro-Oncology. 101: 155-9. PMID 20524043 DOI: 10.1007/S11060-010-0239-0 |
0.408 |
|
| 2011 |
Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, Marcello J, Herndon JE, McLendon RE, Janney D, Friedman AH, Bigner DD, Friedman HS. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. Journal of Neuro-Oncology. 101: 57-66. PMID 20443129 DOI: 10.1007/S11060-010-0217-6 |
0.445 |
|
| 2010 |
Cui B, Johnson SP, Bullock N, Ali-Osman F, Bigner DD, Friedman HS. Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells. Journal of Biomedical Research. 24: 424-35. PMID 23554659 DOI: 10.1016/S1674-8301(10)60057-7 |
0.305 |
|
| 2010 |
Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. The Oncologist. 15: 1329-34. PMID 21147867 DOI: 10.1634/Theoncologist.2010-0105 |
0.44 |
|
| 2010 |
Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4722-9. PMID 20921459 DOI: 10.1200/Jco.2010.28.6963 |
0.348 |
|
| 2010 |
Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe A, Hamilton M, Rich JN, Norfleet JA, Gururangan S, Friedman HS, Reardon DA. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro-Oncology. 12: 1300-10. PMID 20716591 DOI: 10.1093/Neuonc/Noq099 |
0.434 |
|
| 2010 |
Jones LW, Mourtzakis M, Peters KB, Friedman AH, West MJ, Mabe SK, Kraus WE, Friedman HS, Reardon DA. Changes in functional performance measures in adults undergoing chemoradiation for primary malignant glioma: a feasibility study. The Oncologist. 15: 636-47. PMID 20484122 DOI: 10.1634/Theoncologist.2009-0265 |
0.313 |
|
| 2010 |
Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3069-75. PMID 20479404 DOI: 10.1200/Jco.2009.26.8789 |
0.457 |
|
| 2010 |
Augustine CK, Jung SH, Sohn I, Yoo JS, Yoshimoto Y, Olson JA, Friedman HS, Ali-Osman F, Tyler DS. Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma. Molecular Cancer Therapeutics. 9: 779-90. PMID 20371714 DOI: 10.1158/1535-7163.Mct-09-0764 |
0.334 |
|
| 2010 |
Toshimitsu H, Yoshimoto Y, Augustine CK, Padussis JC, Yoo JS, Angelica Selim M, Pruitt SK, Friedman HS, Ali-Osman F, Tyler DS. Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma. Annals of Surgical Oncology. 17: 2247-54. PMID 20182810 DOI: 10.1245/S10434-010-0971-X |
0.325 |
|
| 2010 |
Sampson JH, Archer G, Pedain C, Wembacher-Schröder E, Westphal M, Kunwar S, Vogelbaum MA, Coan A, Herndon JE, Raghavan R, Brady ML, Reardon DA, Friedman AH, Friedman HS, RodrÃguez-Ponce MI, et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. Journal of Neurosurgery. 113: 301-9. PMID 20020841 DOI: 10.3171/2009.11.Jns091052 |
0.3 |
|
| 2010 |
Aliabadi H, Vredenburgh JJ, Everson RG, Desjardins A, Friedman HS, McLendon RE, Tucci DL, Sampson JH. Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration. Journal of Neuro-Oncology. 98: 427-30. PMID 20020179 DOI: 10.1007/S11060-009-0091-2 |
0.367 |
|
| 2010 |
Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE, Marcello J, Norfleet JA, McLendon RE, Sampson JH, Friedman HS. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. Journal of Neuro-Oncology. 96: 219-30. PMID 19562254 DOI: 10.1007/S11060-009-9950-0 |
0.474 |
|
| 2010 |
Gururangan S, Vredenburgh JJ, Desjardins A, Peters K, Herndon JE, McLendon RE, Janney D, Friedman HS, Reardon DA. CYP3A-inducing antiepileptics decrease sorafenib exposures: Results of a phase II study in adults with recurrent glioblastoma. Journal of Clinical Oncology. 28: 2089-2089. DOI: 10.1200/Jco.2010.28.15_Suppl.2089 |
0.412 |
|
| 2010 |
Kirkpatrick J, Vredenburgh JJ, Reardon DA, Desjardins A, Peters K, Gururangan S, Herndon JE, Marcello J, Woodring S, Friedman HS. Phase I trial of the addition of oral topotecan to standard 5-day temozolomide for malignant gliomas. Journal of Clinical Oncology. 28: 2073-2073. DOI: 10.1200/Jco.2010.28.15_Suppl.2073 |
0.407 |
|
| 2010 |
Peters K, Desjardins A, Vredenburgh JJ, Dryman B, Gururangan S, Friedman HS, Reardon DA. Imatinib mesylate plus hydroxyurea for adults with recurrent/progressive low-grade glioma: Final phase II study results. Journal of Clinical Oncology. 28: 2060-2060. DOI: 10.1200/Jco.2010.28.15_Suppl.2060 |
0.416 |
|
| 2010 |
Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Norfleet J, Gururangan S, Friedman HS, Reardon DA. Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results. Journal of Clinical Oncology. 28: 2055-2055. DOI: 10.1200/Jco.2010.28.15_Suppl.2055 |
0.424 |
|
| 2010 |
Desjardins A, Vredenburgh JJ, Reardon DA, Herndon JE, Marcello J, Peters K, Gururangan S, Sathornsumetee S, Rich JN, Friedman HS. Long-term survival from the initial trial of bevacizumab and irinotecan. Journal of Clinical Oncology. 28: 2045-2045. DOI: 10.1200/Jco.2010.28.15_Suppl.2045 |
0.443 |
|
| 2010 |
Brickhouse A, Vredenburgh JJ, Gururangan S, Reardon DA, Desjardins A, Peters K, Herndon JE, Norfleet J, Marcello J, Friedman HS. Phase I trial of vandetanib and oral etoposide (VP-16) for recurrent malignant gliomas (MG). Journal of Clinical Oncology. 28: 2038-2038. DOI: 10.1200/Jco.2010.28.15_Suppl.2038 |
0.326 |
|
| 2010 |
Vredenburgh JJ, Desjardins A, Reardon DA, Peters K, Kirkpatrick J, Herndon JE, Marcello J, Bailey L, Threatt S, Friedman HS. Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology. 28: 2023-2023. DOI: 10.1200/Jco.2010.28.15_Suppl.2023 |
0.4 |
|
| 2010 |
Cloughesy T, Vredenburgh JJ, Day B, Das A, Friedman HS. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. Journal of Clinical Oncology. 28: 2008-2008. DOI: 10.1200/Jco.2010.28.15_Suppl.2008 |
0.378 |
|
| 2010 |
Sampson JH, Archer GE, Schmittling R, Herndon JE, Coan AD, Reardon DA, Verdenburgh J, Desjardins A, Dechkovskaia A, McGehee-Norman S, Lally-Goss D, Perry BA, Friedman A, Friedman HS, Bigner DD, et al. Abstract 5611: Interleukin-2 receptor α (IL-2R α/CD25)-specific antibodies eliminate regulatory T-cells (TRegs) and enhance tumor-specific immune responses Cancer Research. 70: 5611-5611. DOI: 10.1158/1538-7445.Am10-5611 |
0.317 |
|
| 2010 |
Smith MA, Maris JM, Courtright J, Friedman HS, Kier ST, Lock RB, Carol H, Gorlick R, Kolb EA, Kang M, Reynolds CP, Morton CL, Houghton PJ. Abstract 5266: Pediatric Preclinical Testing Program (PPTP) evaluation of the CDK inhibitor SCH 727965 Cancer Research. 70: 5266-5266. DOI: 10.1158/1538-7445.Am10-5266 |
0.397 |
|
| 2010 |
Houghton PJ, Maris JM, Courtright J, Friedman HS, Kier ST, Lock RB, Carol H, Gorlick R, Kolb EA, Kang M, Reynolds CP, Morton CL, Smith MA. Abstract 5265: Pediatric preclinical testing program (PPTP) stage 1 evaluation of BMS-754807 IGF-1 receptor inhibitor Cancer Research. 70: 5265-5265. DOI: 10.1158/1538-7445.Am10-5265 |
0.383 |
|
| 2009 |
Wefel JS, Cloughesy T, Zazzali J, Yi J, Friedman HS. Neurocognitive function in patients with glioblastoma multiforme in first or second relapse treated with bevacizumab in the BRAIN study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2056. PMID 27964669 DOI: 10.1200/Jco.2009.27.15_Suppl.2056 |
0.393 |
|
| 2009 |
Vredenburgh JJ, Desjardins A, Reardon DA, Peters K, Herndon JE, Kirkpatrick J, Gururangan S, Bailey L, Friedman AH, Friedman HS. Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2015. PMID 27964581 DOI: 10.1200/Jco.2009.27.15_Suppl.2015 |
0.372 |
|
| 2009 |
Herndon J, Vredenburgh J, Reardon D, Desjardins A, Peters K, Gururangan S, Norfleet J, Friedman A, Bigner D, Friedman HS. Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e13016. PMID 27962830 DOI: 10.1200/Jco.2009.27.15_Suppl.E13016 |
0.366 |
|
| 2009 |
Friedman HS, Vredenburgh JJ, Desjardins A, Janney DE, Peters KB, Friedman AH, Gururangan S, Reardon DA. A phase I study of sunitinib plus irinotecan in the treatment of patients with recurrent malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e13024. PMID 27962793 DOI: 10.1200/Jco.2009.27.15_Suppl.E13024 |
0.424 |
|
| 2009 |
Peters K, Desjardins A, Reardon DA, Perry S, Herndon JE, Bailey L, Friedman AH, Friedman HS, Bigner DD, Vredenburgh JJ. Temozolomide (TMZ) and bevacizumab (BV) as initial treatment for unresectable or multifocal glioblastoma multiforme (GBM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e13025. PMID 27962792 DOI: 10.1200/Jco.2009.27.15_Suppl.E13025 |
0.443 |
|
| 2009 |
Kirkpatrick JP, Vredenburgh JJ, Desjardins A, Gururangan S, Peters KB, Boulton ST, Friedman AH, Friedman HS, Reardon DA. Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e13007. PMID 27962760 DOI: 10.1200/Jco.2009.27.15_Suppl.E13007 |
0.352 |
|
| 2009 |
Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE, Marcello JE, Norfleet J, Friedman AH, Bigner DD, Friedman HS. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. British Journal of Cancer. 101: 1986-94. PMID 19920819 DOI: 10.1038/Sj.Bjc.6605412 |
0.42 |
|
| 2009 |
Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE, Lally-Goss D, McGehee-Norman S, Paolino A, Reardon DA, Friedman AH, Friedman HS, Bigner DD. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Molecular Cancer Therapeutics. 8: 2773-9. PMID 19825799 DOI: 10.1158/1535-7163.Mct-09-0124 |
0.374 |
|
| 2009 |
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4733-40. PMID 19720927 DOI: 10.1200/Jco.2008.19.8721 |
0.427 |
|
| 2009 |
Bektas M, Johnson SP, Poe WE, Bigner DD, Friedman HS. A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells. Cancer Chemotherapy and Pharmacology. 64: 1053-8. PMID 19597728 DOI: 10.1007/S00280-009-1063-0 |
0.3 |
|
| 2009 |
Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Sampson JH, McLendon RE, Herndon JE, Friedman HS. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. Journal of Neuro-Oncology. 95: 393-400. PMID 19533023 DOI: 10.1007/S11060-009-9937-X |
0.459 |
|
| 2009 |
Affronti ML, Heery CR, Herndon JE, Rich JN, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Bigner DD, Friedman HS. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer. 115: 3501-11. PMID 19514083 DOI: 10.1002/Cncr.24398 |
0.404 |
|
| 2009 |
Perry SL, Bohlin C, Reardon DA, Desjardins A, Friedman AH, Friedman HS, Vredenburgh JJ. Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. Journal of Neuro-Oncology. 95: 129-34. PMID 19415455 DOI: 10.1007/S11060-009-9911-7 |
0.435 |
|
| 2009 |
Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Friedman HS. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. Cancer. 115: 2964-70. PMID 19402172 DOI: 10.1002/Cncr.24336 |
0.353 |
|
| 2009 |
Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Walker A, Friedman HS. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Neuro-Oncology. 11: 556-61. PMID 19289491 DOI: 10.1215/15228517-2009-007 |
0.322 |
|
| 2009 |
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, et al. IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine. 360: 765-73. PMID 19228619 DOI: 10.1056/Nejmoa0808710 |
0.315 |
|
| 2009 |
Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Walker A, Friedman HS. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1262-7. PMID 19204199 DOI: 10.1200/Jco.2008.18.8417 |
0.397 |
|
| 2009 |
Quinn JA, Jiang SX, Carter J, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Threatt S, Friedman HS. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1064-8. PMID 19188181 DOI: 10.1158/1078-0432.Ccr-08-2130 |
0.39 |
|
| 2009 |
Augustine CK, Yoo JS, Potti A, Yoshimoto Y, Zipfel PA, Friedman HS, Nevins JR, Ali-Osman F, Tyler DS. Genomic and molecular profiling predicts response to temozolomide in melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 502-10. PMID 19147755 DOI: 10.1158/1078-0432.Ccr-08-1916 |
0.343 |
|
| 2009 |
Kieran MW, Supko JG, Wallace D, Fruscio R, Poussaint TY, Phillips P, Pollack I, Packer R, Boyett JM, Blaney S, Banerjee A, Geyer R, Friedman H, Goldman S, Kun LE, et al. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatric Blood & Cancer. 52: 169-76. PMID 19065567 DOI: 10.1002/Pbc.21873 |
0.403 |
|
| 2009 |
Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma. Neuro-Oncology. 11: 80-91. PMID 18784279 DOI: 10.1215/15228517-2008-075 |
0.436 |
|
| 2009 |
Paldino M, Desjardins A, Friedman HS, Vredenburgh JJ, Barboriak DP. Prognostic significance of early changes in the apparent diffusion coefficient that occurs after treatment of patients with glioblastoma multiforme with bevacizumab Journal of Clinical Oncology. 27: 2058-2058. DOI: 10.1200/Jco.2009.27.15_Suppl.2058 |
0.332 |
|
| 2009 |
Sathornsumetee S, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Friedman HS, Reardon DA. Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas Journal of Clinical Oncology. 27: 2045-2045. DOI: 10.1200/Jco.2009.27.15_Suppl.2045 |
0.44 |
|
| 2009 |
Houghton PJ, Maris JM, Courtright J, Friedman HS, Keir ST, Lock RB, Carol H, Kolb EA, Gorlick R, Kang M, Reynolds CP, Morton CL, Smith MA. Abstract C57: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of AZD8055 an inhibitor of mTOR Kinase Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C57 |
0.381 |
|
| 2009 |
Prados M, Cloughesy T, Samant MK, Fang L, Das A, Friedman HS. 8721 Evaluation of objective response as a predictor of survival in bevacizumab-treated patients with glioblastoma at first or second relapse in the BRAIN Study Ejc Supplements. 7: 499-500. DOI: 10.1016/S1359-6349(09)71695-7 |
0.366 |
|
| 2009 |
Vredenburgh J, Wefel J, Cloughesy T, Zazzali J, Samant M, Zheng M, Fang L, Das A, Friedman H. 8707 Clinical assessment of corticosteroid use and neurocognitive function in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study European Journal of Cancer Supplements. 7: 495-496. DOI: 10.1016/S1359-6349(09)71681-7 |
0.336 |
|
| 2009 |
Kirkpatrick JP, Desjardins A, Reardon DA, Friedman AH, Friedman HS, Vredenburgh JJ. Radiotherapy, Temozolomide and Bevacizumab followed by Irinotecan, Temozolomide and Bevacizumab Appears Well-tolerated and Efficacious in Newly Diagnosed Glioblastoma Multiforme: Results from a Phase II Trial International Journal of Radiation Oncology Biology Physics. 75. DOI: 10.1016/J.Ijrobp.2009.07.250 |
0.34 |
|
| 2008 |
Sampson JH, Archer GE, Bigner DD, Davis T, Friedman HS, Keler T, Mitchell DA, Reardon DA, Sawaya R, Heimberger AB. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2011. PMID 27948414 DOI: 10.1200/Jco.2008.26.15_Suppl.2011 |
0.333 |
|
| 2008 |
Quinn JA, Jiang XS, Rich JN, Desjardins A, Vredenburgh JJ, Reardon DA, Gururangan S, Walker AR, Birch R, Friedman AH, Friedman HS. Phase I trial of temozolomide plus O(6)-benzylguanine on three different 5-day temozolomide regimens for patients with progressive glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2084. PMID 27948044 DOI: 10.1200/Jco.2008.26.15_Suppl.2084 |
0.338 |
|
| 2008 |
Desjardins A, Reardon DA, Herndon JE, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7068-73. PMID 18981004 DOI: 10.1158/1078-0432.Ccr-08-0260 |
0.467 |
|
| 2008 |
Keir ST, Farland MM, Lipp ES, Friedman HS. Distress persists in long-term brain tumor survivors with glioblastoma multiforme. Journal of Cancer Survivorship : Research and Practice. 2: 269-74. PMID 18958627 DOI: 10.1007/S11764-008-0069-7 |
0.38 |
|
| 2008 |
Schmittling RJ, Archer GE, Mitchell DA, Heimberger A, Pegram C, Herndon JE, Friedman HS, Bigner DD, Sampson JH. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. Journal of Immunological Methods. 339: 74-81. PMID 18775433 DOI: 10.1016/J.Jim.2008.08.004 |
0.315 |
|
| 2008 |
Gururangan S, Krauser J, Watral MA, Driscoll T, Larrier N, Reardon DA, Rich JN, Quinn JA, Vredenburgh JJ, Desjardins A, McLendon RE, Fuchs H, Kurtzberg J, Friedman HS. Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro-Oncology. 10: 745-51. PMID 18755919 DOI: 10.1215/15228517-2008-044 |
0.408 |
|
| 2008 |
Kadota RP, Mahoney DH, Doyle J, Duerst R, Friedman H, Holmes E, Kun L, Zhou T, Pollack IF. Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma. Pediatric Blood & Cancer. 51: 675-8. PMID 18623206 DOI: 10.1002/Pbc.21655 |
0.409 |
|
| 2008 |
Ashley DM, Riffkin CD, Lovric MM, Mikeska T, Dobrovic A, Maxwell JA, Friedman HS, Drummond KJ, Kaye AH, Gan HK, Johns TG, Hawkins CJ. In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs. British Journal of Cancer. 99: 294-304. PMID 18594532 DOI: 10.1038/Sj.Bjc.6604459 |
0.328 |
|
| 2008 |
Everson RG, Graner MW, Gromeier M, Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS, Friedman AH, Bigner DD, Sampson JH. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. Expert Review of Anticancer Therapy. 8: 717-32. PMID 18471045 DOI: 10.1586/14737140.8.5.717 |
0.338 |
|
| 2008 |
Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, Friedman HS, Greer K, Herndon JE, Kunwar S, McLendon RE, Paolino A, Petry NA, Provenzale JM, Reardon DA, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro-Oncology. 10: 320-9. PMID 18403491 DOI: 10.1215/15228517-2008-012 |
0.427 |
|
| 2008 |
Reardon DA, Desjardins A, Vredenburgh JJ, Sathornsumetee S, Rich JN, Quinn JA, Lagattuta TF, Egorin MJ, Gururangan S, McLendon R, Herndon JE, Friedman AH, Salvado AJ, Friedman HS. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro-Oncology. 10: 330-40. PMID 18359865 DOI: 10.1215/15228517-2008-003 |
0.407 |
|
| 2008 |
Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE, McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, ... ... Friedman HS, et al. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro-Oncology. 10: 182-9. PMID 18287339 DOI: 10.1215/15228517-2007-053 |
0.415 |
|
| 2008 |
Gururangan S, Turner CD, Stewart CF, O'Shaughnessy M, Kocak M, Poussaint TY, Phillips PC, Goldman S, Packer R, Pollack IF, Blaney SM, Karsten V, Gerson SL, Boyett JM, Friedman HS, et al. Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 1124-30. PMID 18281546 DOI: 10.1158/1078-0432.Ccr-07-4242 |
0.362 |
|
| 2008 |
Sathornsumetee S, Cao Y, Marcello JE, Herndon JE, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 271-8. PMID 18182667 DOI: 10.1200/Jco.2007.13.3652 |
0.411 |
|
| 2008 |
Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ, Bigner DD. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 30-8. PMID 18077533 DOI: 10.2967/Jnumed.107.046938 |
0.437 |
|
| 2008 |
Maron R, Vredenburgh JJ, Desjardins A, Reardon DA, Quinn JA, Rich JN, Gururangan S, Wagner SA, Salacz ME, Friedman HS. Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM) Journal of Clinical Oncology. 26: 2074-2074. DOI: 10.1200/Jco.2008.26.15_Suppl.2074 |
0.346 |
|
| 2008 |
Salacz ME, Desjardins A, Quinn JA, Rich JN, Vredenburgh JJ, Sathornsumetee S, Goli K, Friedman HS, Reardon DA. Treatment of adults with recurrent progressive low-grade glioma using imatinib mesylate and hydroxyurea Journal of Clinical Oncology. 26: 2071-2071. DOI: 10.1200/Jco.2008.26.15_Suppl.2071 |
0.374 |
|
| 2008 |
Friedman HS, Desjardins A, Vredenburgh JJ, Rich JN, Sathornsumetee S, Gururangan S, Quinn JA, Reardon DA. Phase II trial of erlotinib plus sirolimus for recurrent glioblastoma multiforme (GBM) Journal of Clinical Oncology. 26: 2062-2062. DOI: 10.1200/Jco.2008.26.15_Suppl.2062 |
0.405 |
|
| 2008 |
Kirkpatrick JP, Rich JN, Vredenburgh JJ, Desjardins A, Quinn JA, Gururangan S, Sathornsumetee S, Egorin MJ, Friedman HS, Reardon DA. Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG) Journal of Clinical Oncology. 26: 2057-2057. DOI: 10.1200/Jco.2008.26.15_Suppl.2057 |
0.398 |
|
| 2008 |
Mitchell D, Archer GE, Bigner DD, Friedman HS, Lally-Goss D, Herndon JE, McGehee S, McLendon R, Reardon DA, Sampson JH. Efficacy of a phase II vaccine targeting Cytomegalovirus antigens in newly diagnosed GBM Journal of Clinical Oncology. 26: 2042-2042. DOI: 10.1200/Jco.2008.26.15_Suppl.2042 |
0.377 |
|
| 2008 |
Rich JN, Desjardins A, Sathornsumetee S, Vredenburgh JJ, Quinn JA, Gururangan S, Friedman AH, Friedman HS, Reardon DA. Phase II study of bevacizumab and etoposide in patients with recurrent malignant glioma Journal of Clinical Oncology. 26: 2022-2022. DOI: 10.1200/Jco.2008.26.15_Suppl.2022 |
0.453 |
|
| 2008 |
Wagner SA, Desjardins A, Reardon DA, Marcello J, Herndon JE, Quinn JA, Rich JN, Sathornsumetee S, Friedman HS, Vredenburgh JJ. Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas Journal of Clinical Oncology. 26: 2021-2021. DOI: 10.1200/Jco.2008.26.15_Suppl.2021 |
0.355 |
|
| 2008 |
Cloughesy TF, Prados MD, Wen PY, Mikkelsen T, Abrey LE, Schiff D, Yung WK, Maoxia Z, Dimery I, Friedman HS. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) Journal of Clinical Oncology. 26. DOI: 10.1200/Jco.2008.26.15_Suppl.2010B |
0.39 |
|
| 2008 |
Sathornsumetee S, Vredenburgh JJ, Rich JN, Desjardins A, Quinn JA, Mathe AE, Gururangan S, Friedman AH, Friedman HS, Reardon DA. Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme Journal of Clinical Oncology. 26: 13008-13008. DOI: 10.1200/Jco.2008.26.15_Suppl.13008 |
0.441 |
|
| 2007 |
Bota DA, Desjardins A, Quinn JA, Affronti ML, Friedman HS. Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas. Therapeutics and Clinical Risk Management. 3: 707-15. PMID 18472995 |
0.312 |
|
| 2007 |
Broniscer A, Gururangan S, MacDonald TJ, Goldman S, Packer RJ, Stewart CF, Wallace D, Danks MK, Friedman HS, Poussaint TY, Kun LE, Boyett JM, Gajjar A. Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6712-8. PMID 18006772 DOI: 10.1158/1078-0432.Ccr-07-1016 |
0.392 |
|
| 2007 |
Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 4722-9. PMID 17947719 DOI: 10.1200/Jco.2007.12.2440 |
0.455 |
|
| 2007 |
Hjelmeland AB, Lattimore KP, Fee BE, Shi Q, Wickman S, Keir ST, Hjelmeland MD, Batt D, Bigner DD, Friedman HS, Rich JN. The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. Molecular Cancer Therapeutics. 6: 2449-57. PMID 17766837 DOI: 10.1158/1535-7163.Mct-07-0155 |
0.337 |
|
| 2007 |
Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 110: 1542-50. PMID 17705175 DOI: 10.1002/Cncr.22961 |
0.457 |
|
| 2007 |
Friedman HS, Maxwell J. The fallacy of single-agent chemotherapy for cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 3550; author reply 3. PMID 17687162 DOI: 10.1200/Jco.2007.12.3596 |
0.37 |
|
| 2007 |
Badruddoja MA, Keir ST, King I, Zeidner J, Vredenburgh JJ, Muhlbaier LH, Bigner DD, Friedman HS. Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice. Neuro-Oncology. 9: 240-4. PMID 17522334 DOI: 10.1215/15228517-2007-011 |
0.376 |
|
| 2007 |
McLendon RE, Akabani G, Friedman HS, Reardon DA, Cleveland L, Cokgor I, Herndon JE, Wikstrand C, Boulton ST, Friedman AH, Bigner DD, Zalutsky MR. Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nuclear Medicine and Biology. 34: 405-13. PMID 17499730 DOI: 10.1016/J.Nucmedbio.2007.01.009 |
0.423 |
|
| 2007 |
Yoshimoto Y, Augustine CK, Yoo JS, Zipfel PA, Selim MA, Pruitt SK, Friedman HS, Ali-Osman F, Tyler DS. Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. Molecular Cancer Therapeutics. 6: 1492-500. PMID 17483437 DOI: 10.1158/1535-7163.Mct-06-0718 |
0.39 |
|
| 2007 |
Gururangan S, Fisher MJ, Allen JC, Herndon JE, Quinn JA, Reardon DA, Vredenburgh JJ, Desjardins A, Phillips PC, Watral MA, Krauser JM, Friedman AH, Friedman HS. Temozolomide in children with progressive low-grade glioma. Neuro-Oncology. 9: 161-8. PMID 17347491 DOI: 10.1215/15228517-2006-030 |
0.408 |
|
| 2007 |
Vredenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 1253-9. PMID 17317837 DOI: 10.1158/1078-0432.Ccr-06-2309 |
0.448 |
|
| 2007 |
Sampson JH, Brady ML, Petry NA, Croteau D, Friedman AH, Friedman HS, Wong T, Bigner DD, Pastan I, Puri RK, Pedain C. Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery. 60: ONS89-98; discussion. PMID 17297371 DOI: 10.1227/01.Neu.0000249256.09289.5F |
0.322 |
|
| 2007 |
Pollack IF, Jakacki RI, Blaney SM, Hancock ML, Kieran MW, Phillips P, Kun LE, Friedman H, Packer R, Banerjee A, Geyer JR, Goldman S, Poussaint TY, Krasin MJ, Wang Y, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro-Oncology. 9: 145-60. PMID 17293590 DOI: 10.1215/15228517-2006-031 |
0.458 |
|
| 2007 |
Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. Journal of Neuro-Oncology. 83: 53-60. PMID 17245623 DOI: 10.1007/S11060-006-9302-2 |
0.457 |
|
| 2007 |
Badruddoja MA, Penne K, Desjardins A, Reardon DA, Rich JN, Quinn JA, Sathornsumetee S, Friedman AH, Bigner DD, Herndon JE, Cahill A, Friedman HS, Vredenburgh JJ. Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. Neuro-Oncology. 9: 70-4. PMID 17108065 DOI: 10.1215/15228517-2006-022 |
0.409 |
|
| 2007 |
Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, ... ... Friedman HS, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatric Blood & Cancer. 49: 928-40. PMID 17066459 DOI: 10.1002/Pbc.21078 |
0.369 |
|
| 2007 |
Rich JN, Affronti ML, Day JM, Herndon JE, Quinn JA, Reardon DA, Vredenburgh JJ, Desjardins A, Friedman HS. Overall survival of primary glioblastoma (GBM) patients (pts) receiving carmustine (BCNU) wafers followed by radiation (RT) and concurrent temozolomide (TMZ) plus rotational multi-agent chemotherapy Journal of Clinical Oncology. 25: 2070-2070. DOI: 10.1200/Jco.2007.25.18_Suppl.2070 |
0.338 |
|
| 2007 |
Affronti ML, Day JM, Herndon JE, Rich JN, Quinn JA, Reardon DA, Vredenburgh JJ, Desjardins A, McLendon RE, Friedman HS. Radiation and concurrent temozolomide followed by rotational multi-agent chemotherapy for glioblastoma (GBM) patients Journal of Clinical Oncology. 25: 2068-2068. DOI: 10.1200/Jco.2007.25.18_Suppl.2068 |
0.399 |
|
| 2007 |
Kirkpatrick J, Desjardins A, Quinn J, Rich J, Vredenburgh J, Sathornsumetee S, Gururangan S, Sidor C, Friedman H, Reardon D. Phase II open-label, safety, pharmacokinetic and efficacy study of 2-methoxyestradiol nanocrystal colloidal dispersion administered orally to patients with recurrent glioblastoma multiforme Journal of Clinical Oncology. 25: 2065-2065. DOI: 10.1200/Jco.2007.25.18_Suppl.2065 |
0.442 |
|
| 2007 |
Gururangan S, Turner C, Stewart CF, Kocak M, Poussaint TY, Boyett JM, Kun LE, Karsten V, Gerson SL, Friedman HS. Phase I trial of VNP40101M in children with recurrent brain tumors—A Pediatric Brain Tumor Consortium (PBTC) study Journal of Clinical Oncology. 25: 2059-2059. DOI: 10.1200/Jco.2007.25.18_Suppl.2059 |
0.362 |
|
| 2007 |
Bota DA, Desjardins A, Quinn JA, Rich JN, Vredenburgh JJ, Sathornsumetee S, Goli K, Salvado A, Friedman HS, Reardon DA. Phase II trial of imatinib mesylate and hydroxyurea for adults with recurrent/progressive low-grade glioma Journal of Clinical Oncology. 25: 2053-2053. DOI: 10.1200/Jco.2007.25.18_Suppl.2053 |
0.431 |
|
| 2007 |
Desjardins A, Barboriak DP, Herndon JE, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Friedman HS, Vredenburgh JJ. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11) Journal of Clinical Oncology. 25: 2029-2029. DOI: 10.1200/Jco.2007.25.18_Suppl.2029 |
0.416 |
|
| 2007 |
Sathornsumetee S, Rich JN, Vredenburgh JJ, Desjardins A, Quinn JA, Gururangan S, Egorin MJ, Salvado AJ, Friedman HS, Reardon DA. Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM) Journal of Clinical Oncology. 25: 2027-2027. DOI: 10.1200/Jco.2007.25.18_Suppl.2027 |
0.352 |
|
| 2007 |
Goli KJ, Desjardins A, Herndon JE, Rich JN, Reardon DA, Quinn JA, Sathornsumetee S, Bota DA, Friedman HS, Vredenburgh JJ. Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas Journal of Clinical Oncology. 25: 2003-2003. DOI: 10.1200/Jco.2007.25.18_Suppl.2003 |
0.451 |
|
| 2007 |
Vredenburgh JJ, Bohlin CH, Reardon DA, Desjardins A, Quinn JA, Rich JN, Bota DA, Goli KJ, Friedman HS, Allen DH. Pilot study of dronabinol for adult patients with primary malignant gliomas Journal of Clinical Oncology. 25: 19607-19607. DOI: 10.1200/Jco.2007.25.18_Suppl.19607 |
0.409 |
|
| 2007 |
Jones L, Affronti ML, Bohlin CW, Herndon JE, Quinn JA, Reardon DA, Rich JN, Friedman HS, Vredenburgh JJ. Prevalence of osteoporosis in glioma patients on enzyme inducing anticonvulsants (EIAC) and/or glucocorticoids Journal of Clinical Oncology. 25: 19527-19527. DOI: 10.1200/Jco.2007.25.18_Suppl.19527 |
0.322 |
|
| 2007 |
Bohlin CW, Reardon DA, Desjardins A, Quinn JA, Rich JN, Bota DA, Goli K, Friedman HS, Vredenburgh JJ. Tinzaparin prophylaxis in brain tumor patients Journal of Clinical Oncology. 25: 12506-12506. DOI: 10.1200/Jco.2007.25.18_Suppl.12506 |
0.363 |
|
| 2006 |
Ochiai H, Pernell CT, Archer GE, Chewning TA, McLendon RE, Friedman HS, Sampson JH. Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin. Neurologia Medico-Chirurgica. 46: 485-9; discussion 48. PMID 17062987 DOI: 10.2176/Nmc.46.485 |
0.341 |
|
| 2006 |
Sathornsumetee S, Hjelmeland AB, Keir ST, McLendon RE, Batt D, Ramsey T, Yusuff N, Rasheed BK, Kieran MW, Laforme A, Bigner DD, Friedman HS, Rich JN. AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Research. 66: 8722-30. PMID 16951188 DOI: 10.1158/0008-5472.Can-06-0284 |
0.378 |
|
| 2006 |
Keir ST, Guill AB, Carter KE, Boole LC, Gonzales L, Friedman HS. Differential levels of stress in caregivers of brain tumor patients--observations from a pilot study. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 14: 1258-61. PMID 16775683 DOI: 10.1007/S00520-006-0090-1 |
0.311 |
|
| 2006 |
Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Pegram CN, Provenzale JM, Dowell JM, Rich JN, Vredenburgh JJ, Desjardins A, Sampson JH, et al. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 47: 912-8. PMID 16741299 |
0.338 |
|
| 2006 |
Keir ST, Guill AB, Carter KE, Friedman HS. Stress and intervention preferences of patients with brain tumors. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 14: 1213-9. PMID 16733656 DOI: 10.1007/S00520-006-0087-9 |
0.318 |
|
| 2006 |
Shankar S, Zalutsky MR, Friedman H, Vaidyanathan G. Molecular imaging of alkylguanine-DNA alkyltransferase: further evaluation of radioiodinated derivatives of O6-benzylguanine. Nuclear Medicine and Biology. 33: 399-407. PMID 16631089 DOI: 10.1016/J.Nucmedbio.2005.12.015 |
0.363 |
|
| 2006 |
Jones LW, Guill B, Keir ST, Carter B S K, Friedman HS, Bigner DD, Reardon DA. Patterns of exercise across the cancer trajectory in brain tumor patients. Cancer. 106: 2224-32. PMID 16586497 DOI: 10.1002/Cncr.21858 |
0.345 |
|
| 2006 |
Ueno T, Ko SH, Grubbs E, Yoshimoto Y, Augustine C, Abdel-Wahab Z, Cheng TY, Abdel-Wahab OI, Pruitt SK, Friedman HS, Tyler DS. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. Molecular Cancer Therapeutics. 5: 732-8. PMID 16546988 DOI: 10.1158/1535-7163.Mct-05-0098 |
0.366 |
|
| 2006 |
Gururangan S, Petros WP, Poussaint TY, Hancock ML, Phillips PC, Friedman HS, Bomgaars L, Blaney SM, Kun LE, Boyett JM. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1540-6. PMID 16533779 DOI: 10.1158/1078-0432.Ccr-05-2094 |
0.43 |
|
| 2006 |
Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 1253-65. PMID 16525180 DOI: 10.1200/Jco.2005.04.5302 |
0.408 |
|
| 2006 |
Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, Desjardins A, Sathornsumetee S, Herndon JE, Dowell JM, McLendon RE, Provenzale JM, Sampson JH, Smith RP, Swaisland AJ, Ochs JS, ... ... Friedman HS, et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 860-8. PMID 16467100 DOI: 10.1158/1078-0432.Ccr-05-2215 |
0.44 |
|
| 2006 |
Miralbell R, Fitzgerald TJ, Laurie F, Kessel S, Glicksman A, Friedman HS, Urie M, Kepner JL, Zhou T, Chen Z, Barnes P, Kun L, Tarbell NJ. Radiotherapy in pediatric medulloblastoma: quality assessment of Pediatric Oncology Group Trial 9031. International Journal of Radiation Oncology, Biology, Physics. 64: 1325-30. PMID 16413699 DOI: 10.1016/J.Ijrobp.2005.11.002 |
0.416 |
|
| 2006 |
Ko SH, Ueno T, Yoshimoto Y, Yoo JS, Abdel-Wahab OI, Abdel-Wahab Z, Chu E, Pruitt SK, Friedman HS, Dewhirst MW, Tyler DS. Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 289-97. PMID 16397054 DOI: 10.1158/1078-0432.Ccr-05-0210 |
0.369 |
|
| 2006 |
Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Guruangan S, et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 115-22. PMID 16382120 DOI: 10.1200/Jco.2005.03.4082 |
0.469 |
|
| 2006 |
Chintagumpala MM, Friedman HS, Stewart CF, Kepner J, McLendon RE, Modrich PL, McCluggage C, Burger P, Holmes E, Thompson S, Rutka J, Michalski J, Woo S, Blaney SM, Kun LE, et al. A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. Journal of Neuro-Oncology. 77: 193-8. PMID 16314955 DOI: 10.1007/S11060-005-9024-X |
0.36 |
|
| 2006 |
Heimberger AB, Hussain SF, Aldape K, Sawaya R, Archer GA, Friedman H, Reardon D, Friedman A, Bigner D, Sampson JH. Tumor-specific peptide vaccination in newly-diagnosed patients with GBM Journal of Clinical Oncology. 24: 2529-2529. DOI: 10.1200/Jco.2006.24.18_Suppl.2529 |
0.421 |
|
| 2006 |
Reardon D, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Gururangan S, Egorin MJ, Salvado A, Friedman HS. A phase I trial of imatinib, hydroxyurea and RAD001 for patients with recurrent malignant glioma Journal of Clinical Oncology. 24: 1580-1580. DOI: 10.1200/Jco.2006.24.18_Suppl.1580 |
0.344 |
|
| 2006 |
Desjardins A, Reardon DA, Quinn JA, Rich JN, Vredenburgh JJ, Sathornsumetee S, Salvado A, Friedman HS. Phase II trial of imatinib mesylate and hydroxyurea for grade III malignant gliomas Journal of Clinical Oncology. 24: 1573-1573. DOI: 10.1200/Jco.2006.24.18_Suppl.1573 |
0.352 |
|
| 2006 |
Quinn JA, Vredenburgh JJ, Rich JN, Reardon DA, Desjardins A, Gururangan S, Friedman AH, Carter JH, Threatt S, Friedman HS. Phase II trial of Gliadel plus O6-benzylguanic (O6-BG) for patients with recurrent glioblastoma multiforme Journal of Clinical Oncology. 25: 2036-2036. DOI: 10.1200/Jco.2006.24.18_Suppl.1568 |
0.353 |
|
| 2006 |
Korones DN, Benita-Weiss M, Coyle T, Bushunow P, Mechtler L, Friedman HS. A phase II study of temozolomide and oral VP-16 for adults with recurrent glioma--Final results Journal of Clinical Oncology. 24: 1565-1565. DOI: 10.1200/Jco.2006.24.18_Suppl.1565 |
0.438 |
|
| 2006 |
Sathornsumetee S, Reardon DA, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Egorin M, Salvado A, Friedman HS. An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma Journal of Clinical Oncology. 24: 1560-1560. DOI: 10.1200/Jco.2006.24.18_Suppl.1560 |
0.394 |
|
| 2006 |
Vredenburgh JJ, Bohlin C, Reardon DA, Desjardins A, Quinn J, Rich J, Sathornsumetee S, Marks LB, Friedman AH, Friedman HS. Tinzaparin prophylaxis against thromboembolic complications in brain tumor patients Journal of Clinical Oncology. 24: 1539-1539. DOI: 10.1200/Jco.2006.24.18_Suppl.1539 |
0.425 |
|
| 2006 |
Vredenburgh JJ, Desjardins A, Herndon JE, Quinn J, Rich J, Sathornsumetee S, Friedman HS, Reardon D, Gururangan S, Friedman A. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas Journal of Clinical Oncology. 24: 1506-1506. DOI: 10.1200/Jco.2006.24.18_Suppl.1506 |
0.455 |
|
| 2006 |
Rich JN, Shi Q, Hjelmeland AB, Keir ST, Wickman S, Wu G, Jackson D, Ohmori O, Bigner DD, Friedman HS. A novel low molecular weight inhibitor of focal adhesion kinase and insulin-like growth factor-1 receptor, TAE226, inhibits glioma growth Journal of Clinical Oncology. 24: 11505-11505. DOI: 10.1200/Jco.2006.24.18_Suppl.11505 |
0.342 |
|
| 2006 |
Heery CR, Desjardins A, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Friedman AH, Reardon DA, Friedman HS. Acute toxicity analysis of patients receiving surgery, Gliadel wafer implantation, and postoperative daily temozolomide with radiation therapy for primary high-grade glioma Journal of Clinical Oncology. 24: 11504-11504. DOI: 10.1200/Jco.2006.24.18_Suppl.11504 |
0.337 |
|
| 2005 |
Reardon D, Cloughesy T, Conrad C, Prados M, Xia J, Mietlowski W, Dugan M, Mischel P, Friedman H, Yung A. A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3063. PMID 27945588 DOI: 10.1200/Jco.2005.23.16_Suppl.3063 |
0.334 |
|
| 2005 |
Reardon DA, Egorin MJ, Quinn JA, Rich JN, Rich JN, Gururangan S, Gururangan I, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE, Dowell JM, Badruddoja MA, McLendon RE, ... ... Friedman HS, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 9359-68. PMID 16361636 DOI: 10.1200/Jco.2005.03.2185 |
0.433 |
|
| 2005 |
Rich JN, Sathornsumetee S, Keir ST, Kieran MW, Laforme A, Kaipainen A, McLendon RE, Graner MW, Rasheed BK, Wang L, Reardon DA, Ryan AJ, Wheeler C, Dimery I, Bigner DD, ... Friedman HS, et al. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8145-57. PMID 16299247 DOI: 10.1158/1078-0432.Ccr-05-0319 |
0.362 |
|
| 2005 |
Friedman HS, Bigner DD. Glioblastoma multiforme and the epidermal growth factor receptor. The New England Journal of Medicine. 353: 1997-9. PMID 16282174 DOI: 10.1056/Nejmp058186 |
0.32 |
|
| 2005 |
Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, ... ... Friedman HS, et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7178-87. PMID 16192602 DOI: 10.1200/Jco.2005.06.502 |
0.359 |
|
| 2005 |
Cheng CL, Johnson SP, Keir ST, Quinn JA, Ali-Osman F, Szabo C, Li H, Salzman AL, Dolan ME, Modrich P, Bigner DD, Friedman HS. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Molecular Cancer Therapeutics. 4: 1364-8. PMID 16170028 DOI: 10.1158/1535-7163.Mct-05-0128 |
0.356 |
|
| 2005 |
Greenberg ML, Fisher PG, Freeman C, Korones DN, Bernstein M, Friedman H, Blaney S, Hershon L, Zhou T, Chen Z, Kretschmar C. Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: a pediatric oncology group phase I study. Pediatric Blood & Cancer. 45: 644-8. PMID 16110498 DOI: 10.1002/Pbc.20382 |
0.446 |
|
| 2005 |
Desjardins A, Rich JN, Quinn JA, Vredenburgh J, Gururangan S, Sathornsumetee S, Reardon DA, Friedman AH, Bigner DD, Friedman HS. Chemotherapy and novel therapeutic approaches in malignant glioma. Frontiers in Bioscience : a Journal and Virtual Library. 10: 2645-68. PMID 15970525 DOI: 10.2741/1727 |
0.386 |
|
| 2005 |
Akabani G, Reardon DA, Coleman RE, Wong TZ, Metzler SD, Bowsher JE, Barboriak DP, Provenzale JM, Greer KL, DeLong D, Friedman HS, Friedman AH, Zhao XG, Pegram CN, McLendon RE, et al. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 46: 1042-51. PMID 15937318 |
0.322 |
|
| 2005 |
Sampson JH, Reardon DA, Friedman AH, Friedman HS, Coleman RE, McLendon RE, Pastan I, Bigner DD. Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. Neuro-Oncology. 7: 90-6. PMID 15701286 DOI: 10.1215/S1152851703000589 |
0.402 |
|
| 2005 |
Blaney SM, Boyett J, Friedman H, Gajjar A, Geyer R, Horowtiz M, Hunt D, Kieran M, Kun L, Packer R, Phillips P, Pollack IF, Prados M, Heideman R. Phase I Clinical Trial of Mafosfamide in Infants and Children Aged 3 Years or Younger With Newly Diagnosed Embryonal Tumors: A Pediatric Brain Tumor Consortium Study (PBTC-001) Journal of Clinical Oncology. 23: 525-531. PMID 15659498 DOI: 10.1200/Jco.2005.06.544 |
0.397 |
|
| 2005 |
Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, Herndon JE, Dowell JM, Friedman AH, Friedman HS. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer. 103: 329-38. PMID 15558802 DOI: 10.1002/Cncr.20776 |
0.452 |
|
| 2005 |
Rich JN, Reardon DA, Quinn JA, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Gururangan S, Lyons P, Bigner DD, Friedman HS. A phase I trial of gefitinib (ZD1839) plus rapamycin for patients with recurrent malignant glioma Journal of Clinical Oncology. 23: 1565-1565. DOI: 10.1200/Jco.2005.23.16_Suppl.1565 |
0.404 |
|
| 2005 |
Sathornsumetee S, Reardon DA, Quinn J, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Lyons P, Salvado A, Friedman HS. A phase I dose escalation study of imatinib mesylate plus standard-dosed temozolomide in the treatment of patients with malignant glioma Journal of Clinical Oncology. 23: 1540-1540. DOI: 10.1200/Jco.2005.23.16_Suppl.1540 |
0.421 |
|
| 2005 |
Friedman HS, Quinn J, Rich J, Vredenburgh J, Desjardins A, Sathornsumetee S, Salvado A, Nikolova Z, Bigner D, Reardon D. Efficacy of imatinib mesylate plus hydroxyurea regimen in the treatment of recurrent malignant glioma: Phase II study results Journal of Clinical Oncology. 23: 1515-1515. DOI: 10.1200/Jco.2005.23.16_Suppl.1515 |
0.435 |
|
| 2005 |
Vredenburgh JJ, Reardon D, Akabani G, Friedman A, Friedman H, McLendon R, Quinn J, Rich J, Zalutsky M, Bigner D. Results of a phase II study of 131 Iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors Journal of Clinical Oncology. 23: 1510-1510. DOI: 10.1200/Jco.2005.23.16_Suppl.1510 |
0.371 |
|
| 2004 |
Badruddoja MA, Reardon DA, Akabani G, Friedman AH, Friedman HS, Rich JN, Quinn JA, Penne K, Vredenburgh JJ, Bigner DD. Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1569. PMID 28015735 DOI: 10.1200/Jco.2004.22.14_Suppl.1569 |
0.388 |
|
| 2004 |
Desjardins A, Quinn JA, Reardon DA, Rich JN, Vredenburgh JJ, Efird C, Friedman HS. Phase II study of thalidomide and daily cyclophosphamide for adults with malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1554. PMID 28015449 DOI: 10.1200/Jco.2004.22.14_Suppl.1554 |
0.352 |
|
| 2004 |
Reardon D, Friedman H, Yung WK, Brada M, Conrad C, Provenzale J, Jackson E, Serajuddin H, Chen B, Laurent D. A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1513. PMID 28015364 DOI: 10.1200/Jco.2004.22.14_Suppl.1513 |
0.358 |
|
| 2004 |
Ueno T, Ko SH, Grubbs E, Pruitt SK, Friedman HS, Tyler DS. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. American Journal of Surgery. 188: 532-7. PMID 15546565 DOI: 10.1016/J.Amjsurg.2004.07.014 |
0.389 |
|
| 2004 |
Shi Q, Bao S, Maxwell JA, Reese ED, Friedman HS, Bigner DD, Wang XF, Rich JN. Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. The Journal of Biological Chemistry. 279: 52200-9. PMID 15469933 DOI: 10.1074/Jbc.M409630200 |
0.326 |
|
| 2004 |
Grubbs EG, Abdel-Wahab O, Cheng TY, Abdel-Wahab Z, Peterson B, Pruitt SK, Colvin OM, Friedman HS, Tyler DS. In-transit melanoma: the role of alkylating-agent resistance in regional therapy. Journal of the American College of Surgeons. 199: 419-27. PMID 15325612 DOI: 10.1016/J.Jamcollsurg.2004.05.271 |
0.364 |
|
| 2004 |
Grubbs EG, Ueno T, Abdel-Wahab O, Cheng TY, Pruitt SK, Michael Colvin O, Friedman HS, Tyler DS. Modulation of resistance to regional chemotherapy in the extremity melanoma model. Surgery. 136: 210-8. PMID 15300182 DOI: 10.1016/J.Surg.2004.04.021 |
0.4 |
|
| 2004 |
Wiltshire RN, Herndon JE, Lloyd A, Friedman HS, Bigner DD, Bigner SH, McLendon RE. Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications. The Journal of Molecular Diagnostics : Jmd. 6: 166-79. PMID 15269292 DOI: 10.1016/S1525-1578(10)60507-7 |
0.329 |
|
| 2004 |
Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Vredenburgh J, Gururangan S, Provenzale JM, Walker A, Schweitzer H, Bigner DD, Tourt-Uhlig S, Herndon JE, Affronti ML, Jackson S, ... ... Friedman HS, et al. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro-Oncology. 6: 145-53. PMID 15134629 DOI: 10.1215/S1152851703000498 |
0.396 |
|
| 2004 |
Reardon DA, Quinn JA, Rich JN, Gururangan S, Vredenburgh J, Sampson JH, Provenzale JM, Walker A, Badruddoja M, Tourt-Uhlig S, Herndon JE, Dowell JM, Affronti ML, Jackson S, Allen D, ... ... Friedman HS, et al. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro-Oncology. 6: 134-44. PMID 15134628 DOI: 10.1215/S1152851703000413 |
0.445 |
|
| 2004 |
Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3216-24. PMID 15131063 DOI: 10.1158/1078-0432.Ccr-03-0521 |
0.308 |
|
| 2004 |
Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE, ... ... Friedman HS, et al. Phase II trial of gefitinib in recurrent glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 133-42. PMID 14638850 DOI: 10.1200/Jco.2004.08.110 |
0.462 |
|
| 2004 |
Geyer J, Boyett J, Douglas J, Phillips P, Young-Poussaint T, Packer R, Friedman H, Prados M, Kieran M, Blaney S, Pollack I, Kun L. Phase I trial of ZD1839 (Iressa™) and radiation in pediatric patients newly diagnosed with brain stem tumors or incompletely resected supratentorial malignant gliomas International Journal of Radiation Oncology*Biology*Physics. 60: S251. DOI: 10.1016/J.Ijrobp.2004.07.020 |
0.394 |
|
| 2003 |
Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. Journal of Neuro-Oncology. 65: 27-35. PMID 14649883 DOI: 10.1023/A:1026290315809 |
0.459 |
|
| 2003 |
Cheng TY, Grubbs E, Abdul-Wahab O, Leu SY, Hung CF, Petros W, Aloia T, Fedrau R, Pruitt S, Colvin M, Friedman H, Tyler D. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. American Journal of Surgery. 186: 460-7. PMID 14599607 DOI: 10.1016/J.Amjsurg.2003.07.019 |
0.343 |
|
| 2003 |
Dreyer ZE, Kadota RP, Stewart CF, Friedman HS, Mahoney DH, Kun LE, McCluggage CW, Burger PC, Kepner J, Heideman RL. Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237. Neuro-Oncology. 5: 261-7. PMID 14565163 DOI: 10.1215/S115285170200056X |
0.454 |
|
| 2003 |
Flowers JL, Hoffman RM, Driscoll TA, Wall ME, Wani MC, Manikumar G, Friedman HS, Dewhirst M, Colvin OM, Adams DJ. The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH. Cancer Chemotherapy and Pharmacology. 52: 253-61. PMID 12783198 DOI: 10.1007/S00280-003-0635-7 |
0.323 |
|
| 2003 |
Gururangan S, McLaughlin C, Quinn J, Rich J, Reardon D, Halperin EC, Herndon J, Fuchs H, George T, Provenzale J, Watral M, McLendon RE, Friedman A, Friedman HS, Kurtzberg J, et al. High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 2187-91. PMID 12775745 DOI: 10.1200/Jco.2003.10.096 |
0.428 |
|
| 2003 |
Cloughesy TF, Filka E, Kuhn J, Nelson G, Kabbinavar F, Friedman H, Miller LL, Elfring GL. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer. 97: 2381-6. PMID 12712460 DOI: 10.1002/Cncr.11306 |
0.447 |
|
| 2003 |
Friedman HS, Keir ST, Houghton PJ. The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. Cancer. 97: 2359-62. PMID 12712457 DOI: 10.1002/Cncr.11305 |
0.386 |
|
| 2003 |
Korones DN, Benita-Weiss M, Coyle TE, Mechtler L, Bushunow P, Evans B, Reardon DA, Quinn JA, Friedman H. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer. 97: 1963-8. PMID 12673724 DOI: 10.1002/cncr.11260 |
0.303 |
|
| 2003 |
Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, ... ... Friedman HS, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 646-51. PMID 12586801 DOI: 10.1200/Jco.2003.01.009 |
0.457 |
|
| 2003 |
McGirt MJ, Bulsara KR, Cummings TJ, New KC, Little KM, Friedman HS, Friedman AH. Prognostic value of magnetic resonance imaging-guided stereotactic biopsy in the evaluation of recurrent malignant astrocytoma compared with a lesion due to radiation effect. Journal of Neurosurgery. 98: 14-20. PMID 12546347 DOI: 10.3171/Jns.2003.98.1.0014 |
0.363 |
|
| 2003 |
Friedman HS. Introduction: Irinotecan in brain tumors Cancer. 97: 2351-2351. DOI: 10.1002/Cncr.11303 |
0.334 |
|
| 2002 |
Gururangan S, Friedman HS. Innovations in design and delivery of chemotherapy for brain tumors. Neuroimaging Clinics of North America. 12: 583-97. PMID 12687913 DOI: 10.1016/S1052-5149(02)00031-X |
0.443 |
|
| 2002 |
Friedman HS, Johnson SP, Colvin OM. Cellular mechanisms of cyclophosphamide resistance: model studies in human medulloblastoma cell lines. Cancer Treatment and Research. 112: 199-209. PMID 12481718 DOI: 10.1007/978-1-4615-1173-1_10 |
0.398 |
|
| 2002 |
Cokgor I, Friedman AH, Friedman HS. Current options for the treatment of neoplastic meningitis. Journal of Neuro-Oncology. 60: 79-88. PMID 12416549 DOI: 10.1023/A:1020200317464 |
0.322 |
|
| 2002 |
Gilbert MR, Friedman HS, Kuttesch JF, Prados MD, Olson JJ, Reaman GH, Zaknoen SL. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-Oncology. 4: 261-7. PMID 12356356 DOI: 10.1093/Neuonc/4.4.261 |
0.426 |
|
| 2002 |
Gururangan S, Cavazos CM, Ashley D, Herndon JE, Bruggers CS, Moghrabi A, Scarcella DL, Watral M, Tourt-Uhlig S, Reardon D, Friedman HS. Phase II study of carboplatin in children with progressive low-grade gliomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 2951-8. PMID 12089224 DOI: 10.1200/Jco.2002.12.008 |
0.416 |
|
| 2002 |
McGirt MJ, Villavicencio AT, Bulsara KR, Friedman HS, Friedman AH. Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases. Journal of Neurosurgery. 96: 941-5. PMID 12005403 DOI: 10.3171/Jns.2002.96.5.0941 |
0.366 |
|
| 2002 |
Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, ... ... Friedman HS, et al. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 2277-83. PMID 11980998 DOI: 10.1200/Jco.2002.09.084 |
0.433 |
|
| 2002 |
Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS, McLendon RE. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Archives of Pathology & Laboratory Medicine. 126: 540-4. PMID 11958658 DOI: 10.1043/0003-9985(2002)126<0540:Mamoai>2.0.Co;2 |
0.388 |
|
| 2002 |
Cloughesy TF, Filka E, Nelson G, Kabbinavar F, Friedman H, Miller LL, Elfring GL. Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. American Journal of Clinical Oncology. 25: 204-8. PMID 11943904 DOI: 10.1097/00000421-200204000-00022 |
0.453 |
|
| 2002 |
Turner CD, Gururangan S, Eastwood J, Bottom K, Watral M, Beason R, McLendon RE, Friedman AH, Tourt-Uhlig S, Miller LL, Friedman HS. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro-Oncology. 4: 102-8. PMID 11916501 DOI: 10.1093/neuonc/4.2.109 |
0.483 |
|
| 2002 |
Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 1389-97. PMID 11870184 DOI: 10.1200/Jco.20.5.1389 |
0.43 |
|
| 2002 |
Heimberger AB, Archer GE, Crotty LE, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery. 50: 158-64; discussion 1. PMID 11844246 DOI: 10.1097/00006123-200201000-00024 |
0.325 |
|
| 2001 |
Friedman HS, Keir ST, Houghton PJ, Lawless AA, Bigner DD, Waters SJ. Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice. Cancer Chemotherapy and Pharmacology. 48: 413-6. PMID 11761460 DOI: 10.1007/S002800100358 |
0.369 |
|
| 2001 |
Cavazos CM, Keir ST, Yoshinari T, Bigner DD, Friedman HS. Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts. Cancer Chemotherapy and Pharmacology. 48: 250-4. PMID 11592348 DOI: 10.1007/S002800100347 |
0.341 |
|
| 2001 |
Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, Herndon JE, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH, Stafford-Fox V, Zaknoen S, Early M, Friedman AH, ... Friedman HS, et al. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-Oncology. 3: 246-50. PMID 11584894 DOI: 10.1093/Neuonc/3.4.246 |
0.438 |
|
| 2001 |
Keir ST, Hausheer F, Lawless AA, Bigner DD, Friedman HS. Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice. Cancer Chemotherapy and Pharmacology. 48: 83-7. PMID 11488529 DOI: 10.1007/S002800000274 |
0.334 |
|
| 2001 |
Struck RF, Tiwari A, Friedman HS, Keir S, Morgan LR, Waud WR. Acyl derivatives of demethylpenclomedine, an antitumor-active, non-neurotoxic metabolites of penclomedine. Cancer Chemotherapy and Pharmacology. 48: 47-52. PMID 11488524 DOI: 10.1007/S002800000255 |
0.33 |
|
| 2001 |
Hurwitz CA, Strauss LC, Kepner J, Kretschmar C, Harris MB, Friedman H, Kun L, Kadota R. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. Journal of Pediatric Hematology Oncology. 23: 277-281. PMID 11464982 DOI: 10.1097/00043426-200106000-00008 |
0.482 |
|
| 2001 |
Ewesuedo RB, Wilson LR, Friedman HS, Moschel RC, Dolan ME. Inactivation of O6-alkylguanine-DNA alkyltransferase by 8-substituted O6-benzylguanine analogs in mice. Cancer Chemotherapy and Pharmacology. 47: 63-9. PMID 11221964 DOI: 10.1007/S002800000202 |
0.305 |
|
| 2000 |
Mahoney DH, Cohen ME, Friedman HS, Kepner JL, Gemer L, Langston JW, James HE, Duffner PK, Kun LE. Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neuro-Oncology. 2: 213-20. PMID 11265230 DOI: 10.1093/Neuonc/2.4.213 |
0.386 |
|
| 2000 |
Brown HG, Kepner JL, Perlman EJ, Friedman HS, Strother DR, Duffner PK, Kun LE, Goldthwaite PT, Burger PC. "Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study. Journal of Neuropathology and Experimental Neurology. 59: 857-65. PMID 11079775 DOI: 10.1093/Jnen/59.10.857 |
0.318 |
|
| 2000 |
Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE, Provenzale JM, et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 3862-72. PMID 11078500 DOI: 10.1200/Jco.2000.18.22.3862 |
0.424 |
|
| 2000 |
Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, ... Friedman H, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. British Journal of Cancer. 83: 588-93. PMID 10944597 DOI: 10.1054/Bjoc.2000.1316 |
0.394 |
|
| 2000 |
Thomas PR, Deutsch M, Kepner JL, Boyett JM, Krischer J, Aronin P, Albright L, Allen JC, Packer RJ, Linggood R, Mulhern R, Stehbens JA, Langston J, Stanley P, Duffner P, ... ... Friedman HS, et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 3004-11. PMID 10944134 DOI: 10.1200/Jco.2000.18.16.3004 |
0.386 |
|
| 2000 |
Bottom KS, Ashley DM, Friedman HS, Longee DC. Evaluation of pre-radiotherapy cyclophosphamide in patients with newly diagnosed glioblastoma multiforme. Writing Committee for The Brain Tumor Center at Duke. Journal of Neuro-Oncology. 46: 151-6. PMID 10894368 DOI: 10.1023/A:1006258026274 |
0.442 |
|
| 2000 |
Keir ST, Dolan ME, Pegg AE, Lawless A, Moschel RC, Bigner DD, Friedman HS. O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials. Cancer Chemotherapy and Pharmacology. 45: 437-40. PMID 10854129 DOI: 10.1007/S002800051016 |
0.366 |
|
| 2000 |
Sampson JH, Crotty LE, Lee S, Archer GE, Ashley DM, Wikstrand CJ, Hale LP, Small C, Dranoff G, Friedman AH, Friedman HS, Bigner DD. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proceedings of the National Academy of Sciences of the United States of America. 97: 7503-8. PMID 10852962 DOI: 10.1073/Pnas.130166597 |
0.376 |
|
| 2000 |
Freeman CR, Kepner J, Kun LE, Sanford RA, Kadota R, Mandell L, Friedman H. A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas? International Journal of Radiation Oncology, Biology, Physics. 47: 561-4. PMID 10837936 DOI: 10.1016/S0360-3016(00)00471-5 |
0.431 |
|
| 2000 |
Castellino RC, Elion GB, Keir ST, Houghton PJ, Johnson SP, Bigner DD, Friedman HS. Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. Cancer Chemotherapy and Pharmacology. 45: 345-9. PMID 10755324 DOI: 10.1007/S002800050050 |
0.375 |
|
| 2000 |
Akabani G, Cokgor I, Coleman RE, González Trotter D, Wong TZ, Friedman HS, Friedman AH, Garcia-Turner A, Herndon JE, DeLong D, McLendon RE, Zhao XG, Pegram CN, Provenzale JM, Bigner DD, et al. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. International Journal of Radiation Oncology, Biology, Physics. 46: 947-58. PMID 10705017 DOI: 10.1016/S0360-3016(99)00500-3 |
0.385 |
|
| 2000 |
Mulne AF, Ducore JM, Elterman RD, Friedman HS, Krischer JP, Kun LE, Shuster JJ, Kadota RP. Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study. Journal of Pediatric Hematology/Oncology. 22: 41-4. PMID 10695820 DOI: 10.1097/00043426-200001000-00008 |
0.431 |
|
| 1999 |
Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 2762-71. PMID 10561351 DOI: 10.1200/Jco.1999.17.9.2762 |
0.454 |
|
| 1999 |
Archer GE, Sampson JH, Lorimer IA, McLendon RE, Kuan CT, Friedman AH, Friedman HS, Pastan IH, Bigner DD. Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 5: 2646-52. PMID 10499644 |
0.305 |
|
| 1999 |
Kadota RP, Stewart CF, Horn M, Kuttesch JF, Burger PC, Kepner JL, Kun LE, Friedman HS, Heideman RL. Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study. Journal of Neuro-Oncology. 43: 43-7. PMID 10448870 DOI: 10.1023/A:1006294102611 |
0.443 |
|
| 1999 |
Bigner SH, Matthews MR, Rasheed BK, Wiltshire RN, Friedman HS, Friedman AH, Stenzel TT, Dawes DM, McLendon RE, Bigner DD. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. The American Journal of Pathology. 155: 375-86. PMID 10433931 DOI: 10.1016/S0002-9440(10)65134-6 |
0.302 |
|
| 1999 |
Kadota RP, Kun LE, Langston JW, Burger PC, Cohen ME, Mahoney DH, Walter AW, Rodman JH, Parent A, Buckley E, Kepner JL, Friedman HS. Cyclophosphamide for the treatment of progressive low-grade astrocytoma: a Pediatric Oncology Group phase II Study. Journal of Pediatric Hematology/Oncology. 21: 198-202. PMID 10363852 DOI: 10.1097/00043426-199905000-00007 |
0.391 |
|
| 1999 |
Sampson JH, Archer GE, Villavicencio AT, McLendon RE, Friedman AH, Bishop WR, Bigner DD, Friedman HS. Treatment of neoplastic meningitis with intrathecal temozolomide. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 5: 1183-8. PMID 10353755 DOI: 10.1097/00006123-199909000-00095 |
0.367 |
|
| 1999 |
Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 1516-25. PMID 10334539 DOI: 10.1200/Jco.1999.17.5.1516 |
0.43 |
|
| 1999 |
Cokgor I, Friedman HS, Friedman AH. Chemotherapy for adults with malignant glioma. Cancer Investigation. 17: 264-72. PMID 10225006 DOI: 10.3109/07357909909040596 |
0.309 |
|
| 1999 |
Mandell LR, Kadota R, Freeman C, Douglass EC, Fontanesi J, Cohen ME, Kovnar E, Burger P, Sanford RA, Kepner J, Friedman H, Kun LE. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. International Journal of Radiation Oncology, Biology, Physics. 43: 959-64. PMID 10192340 DOI: 10.1016/S0360-3016(98)00501-X |
0.47 |
|
| 1999 |
Friedman HS, Kerby T, Fields S, Zilisch JE, Graden D, McLendon RE, Houghton PJ, Arbuck S, Cokgor I, Friedman AH. Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. Cancer. 85: 1160-5. PMID 10091802 DOI: 10.1002/(Sici)1097-0142(19990301)85:5<1160::Aid-Cncr21>3.0.Co;2-F |
0.441 |
|
| 1998 |
Moghrabi A, Friedman HS, Ashley DM, Bottom KS, Kerby T, Stewart E, Bruggers C, Provenzale JM, Champagne M, Hershon L, Watral M, Ryan J, Rasheed K, Lovell S, Korones D, et al. Phase II study of carboplatin (CBDCA) in progressive low-grade gliomas. Neurosurgical Focus. 4: e3. PMID 17168503 DOI: 10.3171/Foc.1998.4.4.6 |
0.411 |
|
| 1998 |
Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 3851-7. PMID 9850030 DOI: 10.1200/Jco.1998.16.12.3851 |
0.389 |
|
| 1998 |
Friedman HS, Kokkinakis DM, Pluda J, Friedman AH, Cokgor I, Haglund MM, Ashley DM, Rich J, Dolan ME, Pegg AE, Moschel RC, McLendon RE, Kerby T, Herndon JE, Bigner DD, et al. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 3570-5. PMID 9817277 DOI: 10.1200/Jco.1998.16.11.3570 |
0.398 |
|
| 1998 |
Duffner PK, Krischer JP, Horowitz ME, Cohen ME, Burger PC, Friedman HS, Kun LE. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Annals of Neurology. 44: 313-6. PMID 9749596 DOI: 10.1002/Ana.410440305 |
0.367 |
|
| 1998 |
Burger PC, Yu IT, Tihan T, Friedman HS, Strother DR, Kepner JL, Duffner PK, Kun LE, Perlman EJ. Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. The American Journal of Surgical Pathology. 22: 1083-92. PMID 9737241 DOI: 10.1097/00000478-199809000-00007 |
0.393 |
|
| 1998 |
Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon JE, Vick NA, Paleologos N, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 2202-12. PMID 9626222 DOI: 10.1200/Jco.1998.16.6.2202 |
0.467 |
|
| 1998 |
Friedman HS, Lovell S, Rasheed K, Friedman AH. Treatment of adults with progressive oligodendroglioma with carboplatin (CBDCA): Preliminary results Medical and Pediatric Oncology. 31: 16-18. PMID 9607424 DOI: 10.1002/(Sici)1096-911X(199807)31:1<16::Aid-Mpo3>3.0.Co;2-2 |
0.466 |
|
| 1998 |
McCowage GB, Friedman HS, Moghrabi A, Kerby T, Ferrell L, Stewart E, Duncan-Brown M, Fuchs HE, Tien R, McLendon RE, Meier L, Kurtzberg J, Ashley D, Colvin OM, Longee DC. Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomas. Medical and Pediatric Oncology. 30: 75-80. PMID 9403013 DOI: 10.1002/(Sici)1096-911X(199802)30:2<75::Aid-Mpo1>3.0.Co;2-X |
0.437 |
|
| 1997 |
Bigner SH, McLendon RE, Fuchs H, McKeever PE, Friedman HS. Chromosomal characteristics of childhood brain tumors. Cancer Genetics and Cytogenetics. 97: 125-34. PMID 9283596 DOI: 10.1016/S0165-4608(96)00404-9 |
0.323 |
|
| 1997 |
Graham ML, Herndon JE, Casey JR, Chaffee S, Ciocci GH, Krischer JP, Kurtzberg J, Laughlin MJ, Longee DC, Olson JF, Paleologus N, Pennington CN, Friedman HS. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 15: 1814-23. PMID 9164190 DOI: 10.1200/Jco.1997.15.5.1814 |
0.416 |
|
| 1997 |
Kurpad SN, Dolan ME, McLendon RE, Archer GE, Moschel RC, Pegg AE, Bigner DD, Friedman HS. Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemotherapy and Pharmacology. 39: 307-16. PMID 9025771 DOI: 10.1007/S002800050577 |
0.368 |
|
| 1997 |
Hare CB, Elion GB, Houghton PJ, Houghton JA, Keir S, Marcelli SL, Bigner DD, Friedman HS. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemotherapy and Pharmacology. 39: 187-91. PMID 8996518 DOI: 10.1007/S002800050558 |
0.401 |
|
| 1997 |
Moghrabi A, Tien R, Fuchs H, Longee D, McLendon R, Friedman HS. False positive images in the follow-up of patients with brain tumors. Medical and Pediatric Oncology. 28: 127-31. PMID 8986148 DOI: 10.1002/(Sici)1096-911X(199702)28:2<127::Aid-Mpo6>3.0.Co;2-M |
0.399 |
|
| 1997 |
Mandell L, Kadota R, Douglass E, Fontanesi J, Freeman C, Cohen M, Kovnar E, Burger P, Sanford R, Kepner J, Friedman H, Kun L. 18 Is it time to rethink the role of hyperfractionated radiotherapy in the management of children with newly-diagnosed brainstem glioma?: Results of a pediatric oncology group phase III trial comparing conventional vs. hyperfractionated radiotherapy International Journal of Radiation Oncology*Biology*Physics. 39: 143. DOI: 10.1016/S0360-3016(97)80575-5 |
0.308 |
|
| 1996 |
Duffner PK, Krischer JP, Burger PC, Cohen ME, Backstrom JW, Horowitz ME, Sanford RA, Friedman HS, Kun LE. Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience. Journal of Neuro-Oncology. 28: 245-56. PMID 8832466 DOI: 10.1007/Bf00250203 |
0.372 |
|
| 1996 |
Tonda ME, Heideman RL, Petros WP, Friedman HS, Murry DJ, Rodman JH. Carboplatin pharmacokinetics in young children with brain tumors Cancer Chemotherapy and Pharmacology. 38: 395-400. PMID 8765431 DOI: 10.1007/S002800050502 |
0.378 |
|
| 1996 |
Ashley DM, Meier L, Kerby T, Zalduondo FM, Friedman HS, Gajjar A, Kun L, Duffner PK, Smith S, Longee D. Response of recurrent medulloblastoma to low-dose oral etoposide. Journal of Clinical Oncology. 14: 1922-1927. PMID 8656261 DOI: 10.1200/Jco.1996.14.6.1922 |
0.432 |
|
| 1996 |
Mahoney DH, Strother D, Camitta B, Bowen T, Ghim T, Pick T, Wall D, Yu L, Shuster JJ, Friedman H. High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study. Journal of Clinical Oncology. 14: 382-388. PMID 8636747 DOI: 10.1200/Jco.1996.14.2.382 |
0.411 |
|
| 1996 |
Freeman CR, Bourgouin PM, Sanford RA, Cohen ME, Friedman HS, Kun LE. Long term survivors of childhood brain stem gliomas treated with hyperfractionated radiotherapy: Clinical characteristics and treatment related toxicities Cancer. 77: 555-562. PMID 8630965 DOI: 10.1002/(Sici)1097-0142(19960201)77:3<555::Aid-Cncr19>3.0.Co;2-3 |
0.4 |
|
| 1996 |
McLendon RE, Fung KM, Bentley RC, Ahmed Rasheed BK, Trojanowski JQ, Bigner SH, Bigner DD, Friedman HS. Production and characterization of two ependymoma xenografts. Journal of Neuropathology and Experimental Neurology. 55: 540-8. PMID 8627345 DOI: 10.1097/00005072-199605000-00007 |
0.315 |
|
| 1996 |
McCowage G, Tien R, McLendon R, Felsberg G, Fuchs H, Graham ML, Kurtzberg J, Moghrabi A, Ferrell L, Kerby T, Duncan-Brown M, Stewart E, Robertson PL, Colvin OM, Golembe B, ... ... Friedman HS, et al. Successful treatment of childhood pilocytic astrocytomas metastatic to the leptomeninges with high-dose cyclophosphamide. Medical and Pediatric Oncology. 27: 32-9. PMID 8614389 DOI: 10.1002/(Sici)1096-911X(199607)27:1<32::Aid-Mpo7>3.0.Co;2-V |
0.425 |
|
| 1996 |
Ashley DM, Longee D, Tien R, Fuchs H, Graham ML, Kurtzberg J, Casey J, Olson J, Meier L, Ferrell L, Kerby T, Duncan-Brown M, Stewart E, Colvin OM, Pipas JM, ... ... Friedman HS, et al. Treatment of patients with pineoblastoma with high dose cyclophosphamide. Medical and Pediatric Oncology. 26: 387-92. PMID 8614374 DOI: 10.1002/(Sici)1096-911X(199606)26:6<387::Aid-Mpo3>3.0.Co;2-D |
0.434 |
|
| 1996 |
Broome CB, Schiff RI, Friedman HS. Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions Medical and Pediatric Oncology. 26: 105-110. PMID 8531847 DOI: 10.1002/(Sici)1096-911X(199602)26:2<105::Aid-Mpo7>3.0.Co;2-P |
0.369 |
|
| 1995 |
Heideman RL, Douglass EC, Langston JA, Krischer JP, Burger PC, Kovnar EH, Kun LE, Friedman HS, Kadota R. A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: a Pediatric Oncology Group Study. Journal of Neuro-Oncology. 25: 77-84. PMID 8523093 DOI: 10.1007/Bf01054726 |
0.45 |
|
| 1995 |
Batra SK, McLendon RE, Koo JS, Castelino-Prabhu S, Fuchs HE, Krischer JP, Friedman HS, Bigner DD, Bigner SH. Prognostic implications of chromosome 17p deletions in human medulloblastomas. Journal of Neuro-Oncology. 24: 39-45. PMID 8523074 DOI: 10.1007/Bf01052657 |
0.324 |
|
| 1995 |
Bigner DD, Brown M, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Bigner SH, Zhao XG, Wikstrand CJ, Pegram CN. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report. Journal of Neuro-Oncology. 24: 109-22. PMID 8523067 DOI: 10.1007/Bf01052668 |
0.411 |
|
| 1995 |
Friedman HS, Bigner SH, Bigner DD. Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again). Journal of Neuro-Oncology. 24: 103-8. PMID 8523066 DOI: 10.1007/Bf01052667 |
0.344 |
|
| 1995 |
Dolan ME, Pegg AE, Moschel RC, Vishnuvajjala BR, Flora KP, Grever MR, Friedman HS. Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL. Cancer Chemotherapy and Pharmacology. 35: 121-6. PMID 7987987 DOI: 10.1007/Bf00686633 |
0.321 |
|
| 1995 |
Foltz RM, McLendon RE, Friedman HS, Dodge RK, Bigner DD, Dewhirst MW. A pial window model for the intracranial study of human glioma microvascular function. Neurosurgery. 36: 976-84; discussion 9. PMID 7791991 DOI: 10.1227/00006123-199505000-00014 |
0.368 |
|
| 1995 |
Marks LB, Cuthbertson D, Friedman HS. Hematologic toxicity during craniospinal irradiation: the impact of prior chemotherapy. Medical and Pediatric Oncology. 25: 45-51. PMID 7753002 DOI: 10.1002/Mpo.2950250110 |
0.314 |
|
| 1995 |
Duffner PK, Cohen ME, Sanford RA, Horowitz ME, Krischer JP, Burger PC, Friedman HS, Kun LE. Lack of efficacy of postoperative chemotherapy and delayed radiation in very young children with pineoblastoma. Pediatric Oncology Group. Medical and Pediatric Oncology. 25: 38-44. PMID 7753001 DOI: 10.1002/Mpo.2950250109 |
0.369 |
|
| 1995 |
Razzouk BI, Heideman RL, Friedman HS, Jenkins JJ, Kun LE, Fairclough DL, Horowitz ME. A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors. Cancer. 75: 2762-7. PMID 7743483 DOI: 10.1002/1097-0142(19950601)75:11<2762::Aid-Cncr2820751121>3.0.Co;2-2 |
0.454 |
|
| 1995 |
Pastan IH, Archer GE, McLendon RE, Friedman HS, Fuchs HE, Wang QC, Pai LH, Herndon J, Bigner DD. Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model. Proceedings of the National Academy of Sciences of the United States of America. 92: 2765-9. PMID 7708720 DOI: 10.1073/Pnas.92.7.2765 |
0.331 |
|
| 1995 |
Houghton PJ, Cheshire PJ, Hallman JD, Lutz L, Friedman HS, Danks MK, Houghton JA. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemotherapy and Pharmacology. 36: 393-403. PMID 7634381 DOI: 10.1007/Bf00686188 |
0.408 |
|
| 1994 |
Moghrabi A, Friedman HS, McLendon R, Hockenberger B, Tien RD, Halperin EC, Oakes WJ. Arteriovenous malformation mimicking recurrent medulloblastoma. Medical and Pediatric Oncology. 22: 140-3. PMID 8259101 DOI: 10.1002/Mpo.2950220216 |
0.383 |
|
| 1994 |
Friedman HS, Houghton PJ, Schold SC, Keir S, Bigner DD. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemotherapy and Pharmacology. 34: 171-4. PMID 8194169 DOI: 10.1007/Bf00685936 |
0.321 |
|
| 1994 |
Bruggers CS, Friedman HS, Tien R, Delong R. Cerebral atrophy in an infant following treatment with ifosfamide. Medical and Pediatric Oncology. 23: 380-3. PMID 8058012 DOI: 10.1002/Mpo.2950230412 |
0.318 |
|
| 1994 |
Kadota RP, Mandell LR, Fontanesi J, Kovnar EH, Krischer J, Kun LE, Friedman HS. Hyperfractionated Irradiation and Concurrent Cisplatin in Brain Stem Tumors: A Pediatric Oncology Group Pilot Study (9139) Pediatric Neurosurgery. 20: 221-225. PMID 8043459 DOI: 10.1159/000120794 |
0.359 |
|
| 1994 |
Nashold JR, Oakes WJ, Friedman HS, Halperin EC, Soo M, Hockenberger B, Fuller GN, Tien R. Management of pineal non-germinoma germ cell tumor with residual teratoma and normal alpha-fetoprotein. Medical and Pediatric Oncology. 22: 137-9. PMID 7505047 DOI: 10.1002/Mpo.2950220215 |
0.376 |
|
| 1994 |
Cohen ME, Langston JW, Backstrom J, Duffner PK, Mahoney DH, Gemer L, Linggood R, James HE, Shuster J, Fontanesi J, Friedman HS. Neuroimaging characteristics of progressive optic pathway tumors: Pediatric oncology group study Pediatric Neurology. 11: 132. DOI: 10.1016/0887-8994(94)90328-X |
0.309 |
|
| 1993 |
Nelson SC, Friedman HS, Hockenberger B, Vandersteenhoven JJ, Gray L, Touri SL, Oakes WJ. False-positive MRI detection of recurrent or metastatic pediatric infratentorial tumors. Medical and Pediatric Oncology. 21: 350-5. PMID 8492750 DOI: 10.1002/Mpo.2950210508 |
0.374 |
|
| 1993 |
Soo MS, Tien RD, Gray L, Andrews PI, Friedman H. Mesenrhombencephalitis: MR findings in nine patients. Ajr. American Journal of Roentgenology. 160: 1089-93. PMID 8470582 DOI: 10.2214/Ajr.160.5.8470582 |
0.313 |
|
| 1993 |
Bruggers CS, Friedman HS, Fuller GN, Tien RD, Marks LB, Halperin EC, Hockenberger B, Oakes WJ, Hoffman JM. Comparison of serial PET and MRI scans in a pediatric patient with a brainstem glioma. Medical and Pediatric Oncology. 21: 301-6. PMID 8469227 DOI: 10.1002/Mpo.2950210414 |
0.364 |
|
| 1993 |
Castellino S, Elion GB, Griffith OW, Dewhirst M, Kurtzberg J, Cattley RC, Scott P, Bigner DD, Friedman HS. Development of a model of melphalan-induced gastrointestinal toxicity in mice Cancer Chemotherapy and Pharmacology. 31: 376-380. PMID 8431971 DOI: 10.1007/Bf00686151 |
0.304 |
|
| 1993 |
Ashdown BC, Boyko OB, Uglietta JP, Friedman HS, Hockenberger B, Oakes WJ, Fuller GN. Postradiation cerebellar necrosis mimicking tumor: MR appearance. Journal of Computer Assisted Tomography. 17: 124-6. PMID 8419419 DOI: 10.1097/00004728-199301000-00022 |
0.386 |
|
| 1993 |
Freeman CR, Krischer JP, Sanford RA, Cohen ME, Burger PC, del Carpio R, Halperin EC, Munoz L, Friedman HS, Kun LE. Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. International Journal of Radiation Oncology, Biology, Physics. 27: 197-206. PMID 8407392 DOI: 10.1016/0360-3016(93)90228-N |
0.456 |
|
| 1993 |
Duffner PK, Horowitz ME, Krischer JP, Friedman HS, Burger PC, Cohen ME, Sanford RA, Mulhern RK, James HE, Freeman CR. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. The New England Journal of Medicine. 328: 1725-31. PMID 8388548 DOI: 10.1056/Nejm199306173282401 |
0.433 |
|
| 1993 |
Strong JA, Hatten HP, Brown MT, Debatin JF, Friedman HS, Oakes WJ, Tien R. Pilocytic astrocytoma: correlation between the initial imaging features and clinical aggressiveness. Ajr. American Journal of Roentgenology. 161: 369-72. PMID 8333380 DOI: 10.2214/Ajr.161.2.8333380 |
0.306 |
|
| 1993 |
Felker GM, Friedman HS, Dolan ME, Moschel RC, Schold C. Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemotherapy and Pharmacology. 32: 471-476. PMID 8258196 DOI: 10.1007/Bf00685892 |
0.38 |
|
| 1993 |
Garg S, Garg PK, Zhao XG, Friedman HS, Bigner DD, Zalutsky MR. Radioiodination of a monoclonal antibody using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Nuclear Medicine and Biology. 20: 835-42. PMID 8241995 DOI: 10.1016/0969-8051(93)90149-O |
0.316 |
|
| 1993 |
Halperin EC, Friedman HS, Schold SC, Fuchs HE, Oakes WJ, Hockenberger B, Burger PC. Surgery, hyperfractionated craniospinal irradiation, and adjuvant chemotherapy in the management of supratentorial embryonal neuroepithelial neoplasms in children. Surgical Neurology. 40: 278-83. PMID 8211637 DOI: 10.1016/0090-3019(93)90138-Q |
0.388 |
|
| 1993 |
Friedman HS, Dolan ME, Moschel RC, Pegg AE, Felker GM, Rich J, Bigner DD, Schold SC. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. Journal of the National Cancer Institute. 84: 1926-31. PMID 1334154 DOI: 10.1093/Jnci/84.24.1926 |
0.316 |
|
| 1992 |
Smith DC, Vick NA, Trump DL, Friedman HS, Friedman AH, Purvis J, Gauspari A, Schold SC. Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas. Cancer Chemotherapy and Pharmacology. 30: 272-6. PMID 1643694 DOI: 10.1007/Bf00686294 |
0.4 |
|
| 1992 |
Laskowitz DT, Elion GB, Dewhirst MW, Griffith OW, Cattley RC, Bigner DD, Friedman HS. Enhancement of melphalan-induced gastrointestinal toxicity in mice treated with regional hyperthermia and BSO-mediated glutathione depletion International Journal of Hyperthermia. 8: 111-120. PMID 1545157 DOI: 10.3109/02656739209052883 |
0.32 |
|
| 1992 |
Halperin EC, Brizel DM, Honore G, Sontag MR, Griffith OW, Bigner DD, Friedman HS. The radiation dose-response relationship in a human glioma xenograft and an evaluation of the influence of glutathione depletion by buthionine sulfoximine. International Journal of Radiation Oncology, Biology, Physics. 24: 103-9. PMID 1512145 DOI: 10.1016/0360-3016(92)91028-L |
0.378 |
|
| 1992 |
Debatin JF, Nadel SN, Gray L, Friedman HS, Trotter P, Hockenberger B, Oakes WJ. Phase III clinical evaluation of gadoteridol injection: experience in pediatric neuro-oncologic MR imaging. Pediatric Radiology. 22: 93-8. PMID 1501959 DOI: 10.1007/Bf02011303 |
0.352 |
|
| 1992 |
DeLong R, Friedman H, Friedman N, Gustafson K, Oakes J. Methylphenidate in neuropsychological sequelae of radiotherapy and chemotherapy of childhood brain tumors and leukemia. Journal of Child Neurology. 7: 462-463. PMID 1469256 DOI: 10.1177/088307389200700425 |
0.377 |
|
| 1992 |
Malik RK, Fuller GN, Oakes WJ, Tien R, Hockenberger B, Friedman HS, Halperin EC. Back pain and paraplegia in a fifteen-year-old boy. The Journal of Pediatrics. 121: 652-8. PMID 1403406 DOI: 10.1016/S0022-3476(05)81166-7 |
0.309 |
|
| 1992 |
Laskowitz DT, Elion GB, Dewhirst MW, Griffith OW, Savina PM, Blum MR, Prescott DM, Bigner DD, Friedman HS. Hyperthermia-Induced Enhancement of Melphalan Activity against a Melphalan-Resistant Human Rhabdomyosarcoma Xenograft Radiation Research. 129: 218-223. DOI: 10.2307/3578160 |
0.309 |
|
| 1991 |
Bruggers CS, Friedman HS, Phillips PC, Wiener MD, Hockenberger B, Oakes WJ, Buckley EG. Leptomeningeal dissemination of optic pathway gliomas in three children. American Journal of Ophthalmology. 111: 719-23. PMID 2039043 DOI: 10.1016/S0002-9394(14)76778-9 |
0.329 |
|
| 1991 |
Friedman HS, Horowitz M, Oakes WJ. Tumors of the Central Nervous System: Improvement in Outcome Through a Multimodality Approach Pediatric Clinics of North America. 38: 381-391. PMID 2006083 DOI: 10.1016/S0031-3955(16)38083-X |
0.356 |
|
| 1991 |
Wang AM, Elion GB, Friedman HS, Bodell WJ, Bigner DD, Schold SC. Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts Cancer Chemotherapy and Pharmacology. 27: 278-284. PMID 1998983 DOI: 10.1007/Bf00685112 |
0.374 |
|
| 1991 |
Friedman HS, Tuori SL, Hatten HP, Hockenberger B, Vandersteenhoven JJ, Oakes WJ. Inflammatory lesion mimicking a metastatic ependymoma. Neurosurgery. 29: 617-20. PMID 1944848 DOI: 10.1097/00006123-199110000-00025 |
0.317 |
|
| 1991 |
Friedman HS, Oakes WJ, Bigner SH, Wikstrand CJ, Bigner DD. Medulloblastoma: tumor biological and clinical perspectives. Journal of Neuro-Oncology. 11: 1-15. PMID 1919642 DOI: 10.1007/Bf00166992 |
0.362 |
|
| 1991 |
Griebel M, Friedman HS, Halperin EC, Wiener MD, Marks L, Oakes WJ, Hoffman JM, DeLong GR, Schold SC, Hockenberger B. Reversible neurotoxicity following hyperfractionated radiation therapy of brain stem glioma. Medical and Pediatric Oncology. 19: 182-6. PMID 1902547 DOI: 10.1002/Mpo.2950190307 |
0.386 |
|
| 1991 |
Schuster JM, Friedman HS, Bigner DD. Therapeutic Analysis of in Vitro and in Vivo Brain Tumor Models Neurologic Clinics. 9: 375-382. DOI: 10.1016/S0733-8619(18)30291-3 |
0.372 |
|
| 1990 |
Moncino MD, Friedman HS, Kurtzberg J, Pizzo SV. Papillary adenocarcinoma of the renal pelvis in a child: case report and brief review of the literature. Medical and Pediatric Oncology. 18: 81-6. PMID 2403632 DOI: 10.1002/Mpo.2950180118 |
0.303 |
|
| 1990 |
Oakes WJ, Friedman HS, Bigner SH, Bullock NH, Bigner DD. Successful laboratory growth and analysis of CUSA-obtained medulloblastoma samples. Technical note. Journal of Neurosurgery. 72: 821-3. PMID 2324807 DOI: 10.3171/Jns.1990.72.5.0821 |
0.331 |
|
| 1990 |
Lippitz BE, Halperin EC, Griffith OW, Colvin OM, Honore G, Ostertag CB, Bigner DD, Friedman HS. L-buthionine-sulfoximine-mediated radiosensitization in experimental interstitial radiotherapy of intracerebral D-54 MG glioma xenografts in athymic mice. Neurosurgery. 26: 255-60. PMID 2308673 DOI: 10.1097/00006123-199002000-00012 |
0.331 |
|
| 1990 |
Ware R, Friedman HS, Kinney TR, Kurtzberg J, Chaffee S, Falletta JM. Familial erythrophagocytic lymphohistiocytosis: late relapse despite continuous high-dose VP-16 chemotherapy. Medical and Pediatric Oncology. 18: 27-9. PMID 2294389 DOI: 10.1002/Mpo.2950180106 |
0.328 |
|
| 1989 |
Schold SC, Brent TP, von Hofe E, Friedman HS, Mitra S, Bigner DD, Swenberg JA, Kleihues P. O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. Journal of Neurosurgery. 70: 573-7. PMID 2926498 DOI: 10.3171/Jns.1989.70.4.0573 |
0.339 |
|
| 1989 |
Friedman HS, Schold SC, Djang WT, Kurtzberg J, Longee DC, Halperin EC, Falletta JM, Coleman RE, Oakes WJ. Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor. Neurology. 39: 62-62. PMID 2783351 DOI: 10.1212/Wnl.39.1.62 |
0.457 |
|
| 1989 |
Bigner SH, Schold SC, Friedman HS, Mark J, Bigner DD. Chromosomal composition of malignant human gliomas through serial subcutaneous transplantation in athymic mice. Cancer Genetics and Cytogenetics. 40: 111-20. PMID 2758393 DOI: 10.1016/0165-4608(89)90152-0 |
0.351 |
|
| 1989 |
Stine KC, Friedman HS, Kurtzberg J, Filston HC, Baker ME, Lowe J, Falletta JM. Pulmonary septic emboli mimicking metastatic rhabdomyosarcoma. Journal of Pediatric Surgery. 24: 491-3. PMID 2738814 DOI: 10.1016/S0022-3468(89)80410-5 |
0.323 |
|
| 1989 |
Friedman HS, Schold SC, Mahaley MS, Colvin OM, Oakes WJ, Vick NA, Burger PC, Bigner SH, Borowitz M, Halperin EC. Phase II treatment of medulloblastoma and pineoblastoma with melphalan: clinical therapy based on experimental models of human medulloblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 7: 904-11. PMID 2738624 DOI: 10.1200/Jco.1989.7.7.904 |
0.375 |
|
| 1988 |
Bigner SH, Mark J, Friedman HS, Biegel JA, Bigner DD. Structural chromosomal abnormalities in human medulloblastoma. Cancer Genetics and Cytogenetics. 30: 91-101. PMID 3422050 DOI: 10.1016/0165-4608(88)90096-9 |
0.311 |
|
| 1988 |
Ware R, Friedman HS, Filston HC, Chaffee S, Kurtzberg J, Kinney TR, Falletta JM. Childhood hepatic mesenchymoma: successful treatment with surgery and multiple-agent chemotherapy. Medical and Pediatric Oncology. 16: 62-5. PMID 3340065 DOI: 10.1002/Mpo.2950160114 |
0.373 |
|
| 1988 |
Friedman HS. Rational for "eight-in-one" chemotherapy. Journal of Clinical Oncology. 6: 393-395. PMID 3339400 DOI: 10.1200/Jco.1988.6.2.393 |
0.307 |
|
| 1988 |
Skapek SX, Colvin OM, Griffith OW, Groothuis DR, Colapinto EV, Lee Y, Hilton J, Elion GB, Bigner DD, Friedman HS. Buthionine sulfoximine-mediated depletion of glutathione in intracranial human glioma-derived xenografts. Biochemical Pharmacology. 37: 4313-7. PMID 3196356 DOI: 10.1016/0006-2952(88)90612-0 |
0.34 |
|
| 1988 |
Longee DC, Friedman HS, Djang WT, Halperin E, Schold SC, Oakes WJ. Transient late magnetic resonance imaging changes suggesting progression of brain stem glioma: implications for entry criteria for phase II trials. Neurosurgery. 23: 248-253. PMID 3054620 DOI: 10.1227/00006123-198808000-00024 |
0.387 |
|
| 1987 |
Friedman HS, Oakes WJ. The chemotherapy of posterior fossa tumors in childhood. Journal of Neuro-Oncology. 5: 217-229. PMID 3316521 DOI: 10.1007/Bf00151225 |
0.425 |
|
| 1987 |
Kurtzberg J, Friedman HS, Chaffee S, Falletta JM, Kinney TR, Kurlander R, Matthews TJ, Schwartz RS. Efficacy of intravenous gamma globulin in autoimmune-mediated pediatric blood dyscrasias. The American Journal of Medicine. 83: 4-9. PMID 3118707 DOI: 10.1016/0002-9343(87)90544-4 |
0.388 |
|
| 1987 |
Becton DL, Kurtzberg J, Kinney TR, Friedman HS, Chaffee S, Falletta JM. Treatment of lymphohistiocytic erythrophagocytosis with VP-16 and aziridinylbenzoquinone. Medical and Pediatric Oncology. 15: 58-61. PMID 3108638 DOI: 10.1002/Mpo.2950150203 |
0.363 |
|
| 1987 |
Schold SC, Mahaley MS, Vick NA, Friedman HS, Burger PC, DeLong ER, Albright RE, Bullard DE, Khandekar JD, Cairncross JG. Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 5: 464-71. PMID 3029339 DOI: 10.1200/Jco.1987.5.3.464 |
0.423 |
|
| 1986 |
Malik RK, Friedman HS, Djang WT, Falletta JM, Buckley E, Kurtzberg J, Kinney TR, Stine K, Chaffee S, Hayes J. Treatment of trilateral retinoblastoma with vincristine and cyclophosphamide. American Journal of Ophthalmology. 102: 650-6. PMID 3777087 DOI: 10.1016/0002-9394(86)90540-4 |
0.44 |
|
| 1985 |
Mendelson EB, Friedman H, Neiman HL, Calenoff L, Vogelzang RL, Cohen MR. The role of imaging in infertility management. Ajr. American Journal of Roentgenology. 144: 415-20. PMID 3917596 DOI: 10.2214/Ajr.144.2.415 |
0.31 |
|
| 1985 |
Zeltzer PM, Friedman HS, Norris DG, Ragab AH. Criteria and definitions for response and relapse in children with brain tumors. Cancer. 56: 1824-6. PMID 3896461 DOI: 10.1002/1097-0142(19851001)56:7+<1824::Aid-Cncr2820561321>3.0.Co;2-H |
0.372 |
|
| 1985 |
Ambruso DR, Mccabe ERB, Anderson D, Beaudet A, Mahoney DH, Ballas LM, Brandt IK, Brown B, Coleman R, Kinney TR, Friedman HS, Falletta JM, Haymond MW, Simmons P, Keating JP, et al. Infectious and Bleeding Complications in Patients With Glycogenosis lb American Journal of Diseases of Children. 139: 691-697. PMID 3860000 DOI: 10.1001/Archpedi.1985.02140090053027 |
0.317 |
|
| 1985 |
Friedman HS, Schold SC. Rational approaches to the chemotherapy of medulloblastoma. Neurologic Clinics. 3: 843-853. DOI: 10.1016/S0733-8619(18)31013-2 |
0.318 |
|
| 1984 |
Schold SC, Friedman HS, Bjornsson TD, Falletta JM. Treatment of patients with recurrent primary brain tumors with AZQ Neurology. 34: 615-615. PMID 6538653 DOI: 10.1212/Wnl.34.5.615 |
0.426 |
|
| 1984 |
Schold SC, Friedman HS. Human brain tumor xenografts. Progress in Experimental Tumor Research. 28: 18-31. PMID 6484200 DOI: 10.1159/000408235 |
0.323 |
|
| Show low-probability matches. |
